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General Introduction 
Pain is an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage, or described in terms of such damage 
(Bonica, 1979). However, this definition is described in subjective language 
and is difficult to ascribe to animals. There is no standard definition of pain 
in animals. According to Molony and Kent (1997), pain is an aversive 
sensory and emotional experience representing an awareness by the animal 
of damage or threat to the integrity of its tissues. Pain changes the animal’s 
physiology and behavior to reduce or avoid damage, to reduce the likelihood 
of recurrence and to promote recovery. Pain relies on the activation of a 
distinct mode of receptors. 
Pain caused by various factors can be classified into three major types, 
including nociceptive, inflammatory, and neuropathic pain. Nociceptive pain, 
generally of acute origin, is caused by thermal, mechanical or chemical 
stimulations of peripheral nerve fibers. Inflammatory pain is the result of 
tissue injury and inflammation, and is represented in absence of any 
peripheral nerve damage. Neuropathic pain is caused by damage or disease 
affecting any part of the nervous system involved (Ochoa, 2009), and is 
characterized by remarkable plasticity that is the combination of sensory loss 
with paradoxical hypersensitivity (e.g. allodynia, hyperalgesia) (Woolf et al., 
1999). These types exist in form of acute or chronic conditions. Acute and 
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chronic pains show different time courses. Acute pain does not outlast the 
healing process, whereas chronic pain lasts beyond the healing time for an 
injury. Persistent pain plays an important role in the conversion from acute to 
chronic pain conditions (Kehlet et al., 2006). Clinical classification of 
chronic pain is still controversial, although often classified by an associated 
disease (diabetic neuropathy, cancer pain, arthritis). It is characterized by 
extended duration and represents a complex of pathophysiologic actions 
(Fox, 2009), being frequently difficult to treat with a single analgesic and 
shows unpredictable response to analgesics (Martin and Eisenach, 2001). 
From the animal welfare aspect, pain is still a huge concern; farm 
animals are routinely subjected to painful procedures with no analgesics; 
perioperative pain management in small and exotic animals is inconsistent; 
and management of cancer-related and chronic pain remains a challenge 
(Egger et al., 2013). Pain may adversely affect the animal’s quality of life 
(QOL) due to the distress originating from inability to avoid damage. Pain 
exerts a harmful influence on conditions of animals such as appetite, 
behavior and intestinal function. Furthermore, systemic problems can be 
caused by neglect of pain (Egger et al., 2013). 
The management of pain is an important consideration in human 
medicine. Likewise, pain management is regarded as an essential clinical 
component in modern veterinary medicine. As mentioned above, pain 
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management is central to animal welfare and it has been shown to affect 
animal production. For the treatment of pain, veterinary clinicians have a 
number of options consisting of several therapeutic categories such as 
anticonvulsants, α2-agonists, local anesthetics, opioids and non-steroidal 
anti-inflammatory drugs (NSAID). Local anesthetics and NSAIDs are the 
most common drugs used clinically which act at the periphery (Viñuela-
Fernández et al., 2007). Opioids and α2-agonists are widely used to provide 
analgesic effects by acting on the central nervous system (Robertson and 
Taylor, 2004). Opioids have provided the most effective analgesia and are 
the main drug used in both acute and chronic pain management (Fox, 2014). 
Although NSAIDs are effective in pain control, NSAIDs are inadequate for 
the treatment of severe pain because of their lower efficacy compared with 
opioids. Although inflammatory pain responds well to NSAIDs, but 
neuropathic pain due to nerve damage or neural dysfunction dose not (Woolf 
et al., 1999). 
Opioids are widely used to treat pain in both animals and humans and 
are considered to be the most effective and dependable drugs for controlling 
pain in mammals (Egger et al., 2013). Opioids consist of several therapeutic 
categories such as the classical µ-opioid receptor (MOR) agonists (e.g. 
morphine), the partial MOR agonists (e.g. buprenorphine), the mixed opioid 
κ-opioid receptor (KOR) agonists MOR-antagonists (e.g. butorphanol), and 
4 
the atypical opioids (e.g. tramadol). Although there are four currently 
recognized opioid receptors including MOR (µ), KOR (κ), DOR (δ) and 
nociception/orphanin FQ peptide receptor (NOR) (Egger et al., 2013). MOR 
and KOR are the main targets in veterinary medicine for pain control. MOR 
agonists produce more profound analgesic effect as well as more adverse 
effect than KOR agonists in many species (Wright, 2002). KOR agonists are 
also reported to have some central side effects such as dysphoria and 
sedation (Martin and Eisenach, 2001). For these reason, MOR agonists have 
been used for decades in the treatment of moderate to severe pain in both 
human and veterinary medicine (Meldrum, 2003). However, classic MOR 
agonists, such as morphine, are less effective against chronic pain of 
neuropathic or inflammatory origin, although they respond well to acute pain 
(Kalso et al., 2004). This decrease of effectiveness for chronic pain is caused 
by MOR down regulation with long-term therapies which requires increasing 
dose (Dickenson and Suzuki, 2005). Furthermore, classic MOR agonists are 
associated with serious side effects such as nausea, emesis, constipation and 
respiratory depression, limiting their usefulness for the treatment of chronic 
pain. As a consequence, there is still a need to find new agents having a 
better efficacy and safety profile for the treatment of chronic pain. 
An alternative approach to improve the efficacy and safety profile is to 
combine the MOR activation with an additional mode of action (Tzschentke 
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et al., 2006a). Such an additional mechanism may diminish the otherwise 
side effects of the MOR activation (Schroder et al., 2011; Tzschentke et al., 
2006a). Recently, an approach combing MOR activation with norepinephrine 
(NE) and/or serotonin (5-hydroxytrypta-mine [5-HT]) reuptake inhibition 
has been undertaken to improve the therapeutic range of opioid analgesics 
(Tzschentke et al., 2006a; 2007). Agents that block the reuptake of NE 
and/or 5-HT are effective analgesics in the treatment of chronic neuropathic 
pain conditions (Carter and Sullivan, 2002). Moreover, these agents 
potentiate the analgesic effects of opioids such as morphine (Ossipov et al., 
1982). Overall, the analgesic mechanisms of MOR activation and NA/5-HT 
reuptake inhibition manifest complementary modes of action, and 
compounds with combined mechanisms of action may be better suited for 
the treatment of chronic pain (Kress, 2010; Tzschentke et al., 2006a). 
Tramadol (TMD) is the first molecule with dual mechanisms of action 
and produces MOR activation and inhibition of 5-HT and NE reuptake. It 
was first developed in 1962 and has been used for the treatment of pain in 
Germany (Schenck and Arend, 1978). Moreover, it is marketed for pain 
management for cats and dogs in Italy. TMD is a racemate with two 
enantiomers, both of which contribute to analgesic effect via different 
mechanisms (Grond and Sablotzki, 2004). The MOR activation of TMD 
resides in the (+)-tramadol and the metabolite (+)-O-desmethyl-tramadol 
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(M1). On the other hand, the inhibitory activities of 5-HT and NE reuptake 
reside in (+)- and (-)-tramadol, respectively (Grond and Sablotzki, 2004). 
Moreover, most of its effect is the result of the active metabolite M1 
(Tzschentke et al., 2007). This relative contribution of the mechanisms of 
action has been attributed to an unpredictable analgesic effect. Furthermore, 
the formation of M1 depends on the cytochrome P450 (CYP2D6), which is 
polymorphic in humans, and the administration of TMD with standard doses 
produces an unpredictable analgesic effect in humans (Poulsen et al., 1996). 
TMD is metabolized faster to inactive metabolites N-desmethyl-tramadol 
(M2) and O,N-didesmethyl-tramadol (M5), in many animal species (Black et 
al., 2010; Cox et al., 2011; Giorgi et al., 2009a; 2009b; 2009c; 2009d; 2009e; 
KuKanich and Papich, 2004; Souza and Cox, 2011). The clinical analgesic 
effect of TMD is uncertain for some animals, particularly in species that 
metabolize the molecule to inactive metabolites (Giorgi, 2008; Giorgi et al., 
2009c). Recently, PK/PD studies of TMD in dogs have been demonstrated 
that it has not shown analgesic effects in the mechanical and thermal 
nociception test, due to the lack of M1 (Kogel et al., 2014; KuKanich and 
Papich, 2011). Therefore, it is possible that tramadol may not provide as 
effective and safe treatment for pain as in humans (De Sousa et al., 2008; 
Giorgi et al., 2009a; 2009b; 2009c; 2009d; 2009e; 2010). Although, tramadol 
has been reported to be effective in a small number of clinical investigations 
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(Pypendop et al., 2009; Vettorato et al., 2010), the real efficacy of tramadol 
in veterinary medicine is still controversial. 
Tapentadol (TAP) is a novel centrally acting analgesic that combines 
two different mechanisms of action, MOR agonist and NE reuptake 
inhibition (Tzschentke et al., 2007). It has recently been added to the atypical 
opioid class. TAP was first developed in Germany and was launched on the 
European market for human use in 2011. In addition, the US FDA approved 
it in 2008 for the treatment of moderate to severe pain (Hartrick and Rozek, 
2011). Chemically, TAP is 3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2- 
methylpropyl] phenol hydrochloride with two chiral centers (Fig. 1A). It has 
a structure similar to tramadol (Fig.1B). TAP has four stereoisomers as 
follows SS, RS, SR and RR forms, only the RR form being approved as 
analgesic (Jain and Basniwal, 2013). The binding affinity to MOR is 
approximately 10 folds higher than to KOR and DOR (Tzschentke et al., 
2006a; 2007). Although MOR affinity of TAP is approximately 50 folds 
lower than that of morphine, its analgesic potency in a variety of preclinical 
analgesia models was only 2-3 folds lower than that of morphine 
(Tzschentke et al., 2007). The effect of NE reuptake inhibition by TAP was 
similar to that of serotonin norepinephrine reuptake inhibitors (SNRI, e.g. 
venlafaxine) in the rat (Tzschentke et al., 2007). Despite the low MOR 
affinity of TAP, only a slight decrease of analgesic potency was observed, 
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which suggests that the NE reuptake inhibitory effect contributes to its 
analgesic effects (Tzschentke et al., 2006b; 2007). Moreover, a preclinical 
research in a neuropathic pain model showed that TAP acted primarily in the 
spinal cord and its analgesic effect is depended solely on MOR activation 
and NE reuptake inhibition (Bee et al., 2011). TAP also produced the 
antinociceptive effect in a rodent model for diabetic neuropathic pain 
(Christoph et al., 2010). Thus, TAP appears to have analgesic effects in both 
acute pain and in chronic neuropathic pain. 
Furthermore, TAP is consistently two to five times more potent than 
TMD in both the tail flick test and the rat spinal nerve ligation model (Raffa 
et al., 2012). Analgesic effect of TMD is only arisen from its M1, showing 
many other futile metabolites and the other inefficacious (-)-enantiomer out 
of the racemic mixture. As opposed to the metabolic profile of TMD, TAP is 
metabolized predominantly by O-glucuronidation to O-glucuronide, which 
does not show any affinity for MOR and the NE transporter (Tzschentke et 
al., 2007). Thus, there are no active metabolites of TAP and metabolic 
activation is not required for analgesic effect, in contrast to TMD. 
Accordingly, TAP could potentially overcome a number of the disadvantages 
of TMD, since TAP is a pure enantiomer of RR and the parent compound is 
solely responsible for its pharmacological activity. 
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As mentioned above, a typical MOR agonist like morphine produces 
side effects such as nausea and emesis, constipation, respiratory depression, 
addiction, and dependence. According to Matthes et al., (1996), these side 
effects of opioids are mediated by the same MOR subtype. As a consequence, 
it is expected that TAP produces fewer opioid related side effects than 
classical MOR agonists. When compared to classical opioids, TAP induced 
much less nausea and vomiting in ferrets, and the duration of side effects was 
also shorter (Tzschentke et al., 2009). Moreover, the threshold dose for these 
effects was 100 times higher for TAP than for morphine. In accordance with 
these data, TAP had a favorable tolerability than morphine at equianalgesic 
intraperitoneal doses in humans on both (i) gastrointestinal motility assessed 
from charcoal transit and (ii) prostaglandin-induced diarrhea. Additionally, 
systemic administration of TAP in humans is associated with a 2-3 folds 
reduction in the rate of adverse effects reported with oxycodone (Biondi et 
al., 2013) and a better tolerance and physical dependence profile was 
observed (Tzschentke et al., 2006b; 2007). Overall, TAP could be a 
promising novel analgesic with low side effects, however much more data is 
required before it can be recommended for regular use in veterinary 
medicine. 
Veterinary medicine faces the unique challenge of having to treat many 
animal species, including mammals, birds, reptiles and fishes. The main 
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challenge for veterinarians is not just to select a drug but to determine, for 
the selected agent, a rational dosing regimen which is a long and complicated 
endeavor because of differences in the expression of enzymes, receptors and 
signal transduction molecules between species (Giorgi, 2012). Both inter- 
and intra-species differences in drug response can be attributed to either 
variations in pharmacokinetics (PK) or pharmacodynamics (PD), the 
magnitude of which varies from drug to drug (Riviere et al., 1997). 
Generally, the action of each drug depends on the concentration–time profile 
at the site of action; this concept provides a basis for improved drug 
development through the use of PK/PD modeling (Toutain and Lees, 2004). 
The PK and PD data generated in the single dose study is bridged using a 
link model and this linked information may be used as an alternative and 
preferred tool to select rational dosage regimens (both dose and dosing 
interval) for further evaluation in clinical trials. PK/PD assessment is the 
major tool for rational dosage regimen determination, as it quantifies the two 
main sources of interspecies variability. Hence, PK/PD studies are critical 
when a drug is applied to a new animal species. 
The situation of treatment with two or more drugs is common in 
clinical care of humans and animals. The use of multiple drugs that have 
different mechanisms of action may produce the effect more efficaciously 
against a single target or a disease. As described before, the use of classic 
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MOR agonists seem to be remarkably effective against acute pain, but less 
suited to chronic neuropathic pain. Moreover, MOR agonists are 
accompanied by severe side effects. In certain cases, drug combination of 
opioids and analgesics that have different mechanisms of action, may result 
in a synergistic analgesic effect, dose and toxicity reduction, and minimize or 
delay the induction of drug resistance (Chou, 2006). This multimodal therapy 
may offer enhanced effects compared to equianalgesic doses of the 
individual drugs in complex pain condition. Thus, the ideal combination 
regimen would both enhance analgesic efficacy and reduce side effects 
compared to a single drug. 
Several combination studies with classic opioids (particularly 
morphine) have reported that multimodal therapies enhanced analgesic 
effects in various animal models of nociception (Argüelles et al., 2002; 
Hernández-Delgadillo et al., 2002; Kolosov et al., 2012; Miranda et al., 2013; 
Ossipov et al., 1997). Specifically, combination investigations of opioids and 
NSAIDs have been investigated in different animal models: tramadol with 
meloxicam in the sciatic nerve ligated rat model as well as in the formalin 
test, tramadol with metamizol in hind paw test, buprenorphine with 
lumiracoxib in the rat orofacial formalin test (Abass et al., 2014; Capuano et 
al., 2009; Hernández-Delgadillo et al., 2002; Isiordia-Espinoza et al., 2011). 
Recently, a combination investigation of TAP and pregablin has reported 
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that the combination resulted in a synergistic antihypersensitive activity in a 
rat model of neuropathic pain (Christoph et al., 2011). Accordingly, it could 
be expected that the combination of TAP with analgesics with different 
mechanisms of action would improve the efficacy and tolerability profiles in 
animals. 
Flupirtine (FLP) is a centrally acting, non-opioid analgesic that belongs 
to the triaminopyridine class. It was approved in the 1980s in Germany for 
the treatment of several pain states (Devulder, 2010). FLP acts as a selective 
neuronal potassium channel opener having N-methyl-D-aspartate (NMDA) 
receptor antagonism (Kornhuber et al., 1999), however, the exact mechanism 
of action has remained unknown until recently. In addition, it has muscle 
relaxant and anticonvulsant effect in pain management. These properties 
contribute to its therapeutic advantages without the side effects of classic 
opioids or NSAIDs (Szelenyi and Nickel, 1991). In earlier studies, FLP has 
been reported to have no interaction with serotonin, dopamine, nicotine 
receptors or adrenoceptors (Bleyer et al., 1988). In spite of these benefits, the 
use of FLP has been limited due to the side effects such as somnolence and 
dizziness. Consequently, its use has been limited to mild or moderate 
musculoskeletal pain syndromes in humans. However, a molecule with 
NMDA antagonism is likely to have synergistic or additive interactions with 
other analgesics such as morphine (Goodchild et al., 2008a). Several 
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investigations have been reported that FLP enhanced analgesic effects of 
opioids in various animal pain models (Capuano et al., 2011; Goodchild et 
al., 2007; 2008a; 2008b; Kolosov et al., 2012). Previous studies suggest that 
the combination of TAP and FLP may display the synergistic interaction. 
TAP is known to yield high and reliable analgesic effect for the 
treatment of chronic pain with low side effects in humans, as compared to 
classic opioids. If the pronounced efficacy and safety profiles of TAP holds 
true in animals, it would be a useful drug for the treatment of chronic pain in 
companion, industrial and even exotic animals. However, much more data in 
variety of animal species is needed to propose its use in veterinary medicine. 
The aim of this study are: i) to assess the pharmacokinetics of TAP after IV, 
IM and SC injection in healthy cats; ii) to assess the pharmacokinetics of 
TAP after IV and IM injection in healthy goats; iii) to evaluate the PK/PD 
relationship in turtles, after a single IM injection of TAP; iv) to determine the 
antinociceptive effect of TAP and FLP in rats when administered separately 
or in combination, as well as their synergistic interaction. 
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3-[(1R,2R)-3 (dimethylamino)-1-ethyl-2- methylpropyl] phenol hydrochloride  
 
 
(1RS,2RS)- 2-[(dimethylamino)methyl]- 1 -(3-methoxyphenyl)- cyclohexanol 
Fig. 1. Chemical structure of tapentadol hydrochloride (A) and tramadol (B) 
  
A) 
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Chapter 1. Pharmacokinetics of Tapentadol (TAP) after Intravenous 
(IV), Intramuscular (IM) and Subcutaneous (SC) Administration in 
Cats 
 
Abstract 
The aim of the present study was to investigate the pharmacokinetics 
of the novel atypical drug tapentadol (TAP) after intravenous (IV), 
intramuscular (IM) and subcutaneous (SC) injection in six healthy cats. The 
dose rate used was 5 mg/kg and the concentrations of TAP in plasma were 
evaluated using high-performance liquid chromatography. 
Some adverse effects including salivation, agitation and panting, were 
noted, especially following IV administration. In all three administration 
groups, TAP concentrations were detectable in plasma for up to 8 h. 
Bioavailability for each route was almost complete, accounting for 94% and 
90% after IM and SC administrations, respectively. Drug absorption was 
faster after IM than SC administration (0.25 h vs. 0.63 h). The half-life of the 
terminal portion of the plasma concentration curve was not significantly 
different between the three routes of administrations (2–3 h). TAP appears to 
have some variation in its pharmacokinetic features in cats compared to other 
animal species. 
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I. Introduction 
As drug options to provide analgesia in cats are limited compared to 
those available for dogs, cats often receive inadequate analgesia, mainly 
because of the perceived risk of side effects and limited information on 
suitable alternatives (Lascelles et al., 1999). The investigation of new active 
ingredients suitable for feline therapy is therefore critical. Opioids are 
considered prototypical analgesics (Fox, 2010) and are used in veterinary 
medicine not only for analgesia but for their other clinical actions (e.g. anti- 
tussive, antidiarrheal and emetic). The classical strong MOR agonists can 
have significant adverse effects (Vadivelu et al., 2011) and are therefore 
generally licensed as controlled substances (Pascoe, 2000; Clutton, 2010). 
Therfore, atypical opioid drugs (especially tramadol) have gained popularity 
in small animal clinical practice. 
Tramadol is one of the most widely sold atypical opioids. It is 
marketed for pain control of cats and dogs in Italy, although its real efficacy 
in dogs has been questioned (Giorgi, 2008; Giorgi et al., 2009). Since most 
of its effect is the result of the active metabolite M1, tramadol may not be 
safe for use in cats with liver disease. Tramadol possesses a weak agonist 
affinity for the MOR, reducing the typical opioid side effects, which are due 
to the activation of this receptor. However, its efficacy for pain relief, 
especially the relief of chronic pain, is enhanced by a second synergistic 
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mechanism of action, namely norepinephrine (NA) and serotonin (5-HT) 
reuptake (Raffa et al., 1992). Its application is generally limited to the 
treatment of mild to moderate pain and its effect is inferior to the strong 
classical opioids (morphine). 
A new drug, tapentadol (TAP), has recently been added to the atypical 
opioid class. It was launched on the European market for human use in 2011. 
In humans, TAP has a lower incidence of adverse effects compared to 
equianalgesic doses of morphine (Kleinert et al., 2008) and oxycodone 
(Etropolski et al., 2011). TAP has attracted the attention of the veterinary 
world because its MOR affinity is 50-fold less than morphine but 120-fold 
higher than tramadol (Giorgi, 2012). Additionally, its second synergistic 
mechanism of action is known not to involve 5-HT reuptake, reducing the 
possibility of the ‘serotonin storm effect’ reported following rapid IV 
tramadol injections. In brief: (1) TAP is recommended in cases of moderate 
to severe pain (as is morphine); (2) compared to morphine, TAP produced 
much less nausea and vomiting and when these adverse effects were present, 
their duration was shorter (Tzschentke et al., 2009); (3) TAP is not 
restricted/regulated in most European countries; and (4) TAP does not 
require metabolic activation to be effective, so individual variations in drug 
metabolism should have limited effects on efficacy. 
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Very few studies to investigate the clinical uses of TAP have been 
undertaken in the veterinary field. The pharmacokinetic features of TAP 
have been investigated in dogs after IV and oral administration, 
demonstrating very low oral bioavailability (4%; Giorgi et al., 2012a). In a 
study of rabbits undergoing castration, it was reported that TAP had 
excellent efficacy for the reduction of surgical and post-surgical pain (Giorgi 
et al., 2013). 
The aim of this study was to assess the pharmacokinetics of TAP after 
IV, IM and SC injection in healthy cats. 
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II. Materials and Methods 
1. Drugs and reagents 
TAP hydrochloride was supplied as a pure powder (> 99.8% purity; 
Bepharm, China). M1 was used as an internal standard and supplied as pure 
powder (> 99.8% purity; LCG Promochem, Germany). Additionally, high-
performance liquid chromatography (HPLC) grade acetonitrile (ACN), 
dichloromethane (CH2Cl2) and diethyl ether (Et2O) were used in the assays 
(Scharlau, USA), as was analytical grade acetic acid and sodium tetraborate 
decahydrate (BDH, Ireland). HPLC grade water was obtained by distilling 
deionised water produced by a Milli-Q Millipore water system (EDM 
Millipore, Italy). All the other reagents and materials were of analytical 
grade and supplied from commercial sources. The injectable solutions were 
prepared by dissolving the pure TAP hydrochloride powder in sterile saline 
to produce a 5 mg/mL solution, which was then passed through a 0.45 µm 
filter, maintaining sterile conditions. 
 
2. Animals 
Four male and two female mixed-breed cats, aged 3–6 years, with a 
bodyweight of 3.4–4.8 kg, were enrolled in the study. The cats were 
previously determined to be clinically healthy on physical examination, 
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serum chemistry and haematological analyses. Animal care and handling was 
performed according to the provision of the EC council Directive 86/609 
EEC and also according to Institutional Animal Care and Use directives 
issued by the Animal Welfare Committee of the University of Lublin, which 
approved the study protocol. 
 
3. Experimental design 
Cats were randomly assigned to three treatment groups, using six slips 
of paper marked with the numbers 1–6, selected blindly from a box. An open, 
single-dose, three-treatment, three-period crossover design (3 x 3 Latin 
square) was used. All cats were fasted for 12 h overnight before each 
experiment. In the first period, each cat in group I (n = 2) received a single 
IV dose of TAP (5 mg/mL) at 5 mg/kg injected slowly over 2 minutes into 
the left jugular vein. This dose was selected based on previous information 
describing the effectiveness of TAP in laboratory species (Giorgi et al., 
2013). Group II cats (n = 2) received a single IM injection of 5 mg/kg of 
TAP given into the rectus femoris portion of the quadriceps femoris muscle. 
Wash out period is a 1-week for the complete metabolism and 
excretion of TAP. After this period, the groups were rotated and the 
experiment was repeated (second period). After a further interval of 1 week, 
the groups were rotated and the experiment was repeated (third period). By 
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the end of the study, each cat had received TAP by all the three 
administration routes. 
A catheter was placed into the right cephalic vein to facilitate blood 
sampling. Blood samples (1 mL) were collected at 0.08, 0.25, 0.5, 0.75, 1, 
1.5, 2, 4, 6, 8 and 10 h after the administration of TAP and placed in 
collection tubes containing lithium heparin. All blood samples were 
centrifuged within 30 min of collection, at 3,000×g, 4°C for 15 min. The 
harvested plasma was stored at -70 °C and used within 15 days of collection. 
 
4. High performance liquid chromatography (HPLC) 
The concentration of TAP in plasma were determined using HPLC, 
according to the method previously described by Giorgi et al. (2012b). The 
analytical method was briefly re-validated in plasma from the cats. The 
HPLC system was an LC Waters (Waters, USA) consisting of quaternary 
gradient system (600 Controller, Waters, USA), in-line degasser (Waters, 
USA), photodiode array detector (2998 model, Waters, USA), multi lambda 
fluorescence detector (2475 model, Waters, USA) and auto sampler (model 
717 plus, Waters, USA). Data was processed using Empower ProTM 
software (Waters, USA). The chromatographic separation assay was 
performed with a SunFire C18 analytical column (150 x 4.6 mm inner 
diameter, 5 µm particle size, Waters, USA) maintained at 25°C. The mobile 
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phase consisted of ACN (A): 0.2% acetic acid (B) at a flow rate of 1 mL/min. 
Excitation and emission wavelengths were set at 273 and 298 nm, 
respectively. The linear gradient elution system was performed as follows: 
5–95% B (0–20 min), 95–5% B (20–25 min) and 5% B isocratically (25–32 
min). 
 
5. Preparation of plasma samples 
Briefly, 50 µL of IS solution (0.5 µg/mL) and 0.2 mL 0.2 M borate 
buffer adjusted to pH 9.3 were added to a 1.5 mL polypropylene snap cap 
tube (Sarsedt) containing 0.5 mL of plasma. After vortex-mixing, 0.4 mL of 
extraction solvent (Et2O:CH2Cl2 7:3 v/v) was added, the tube was then 
vortexed (30 sec) and shaken for 5 min and then centrifuged for 10 min at 
15,625×g. The organic layer (0.3 mL) was then transferred into a clean 0.5 
mL polypropylene snap cap conical tube, placed in a vortex and then shaken 
with 0.2 mL of back-extraction solvent (0.05M HCl:ACN 1:1 v/v) for 5min, 
before being centrifuged for 10min at 15,625×g. The aqueous phase (50 µL) 
was injected into the HPLC system. 
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6. Pharmacokinetic evaluation 
The pharmacokinetic calculations were carried out using WinNonlin v 
5.3 (Pharsight). Maximum concentration (Cmax) of TAP in plasma and the 
time required to reach Cmax (Tmax) were predicted from the data. The 
concentration at time 0 (C0) for IV administration was estimated by back-
extrapolating from the first two concentration values. The terminal rate 
constant (λ) was determined from the slope of the terminal phase of the 
plasma concentration curve that included a minimum of three points. The 
half-life of the terminal phase (T1/2λz) was calculated using T1/2 = 0.693/λ. 
The area under the concentration vs. time curve (AUC0–∞) was calculated 
using the linear trapezoidal rule. The IM and SC bioavailabilities (F%) were 
calculated from the ratio of the areas under the plasma TAP concentration 
curve after IM or SC and IV administration, respectively, indexed to their 
respective dose: 
F (%) = (AUCIM/SC x DoseIV)/(AUCIV x DoseIM/SC) x 100 
Changes in plasma concentration of TAP were evaluated using the 
standard non-compartmental analysis, and the relative pharmacokinetic 
parameters were determined using standard non-compartmental equations 
(Gabrielsson and Weiner, 2002.). Different models were assessed by visual 
inspection of the curve fits and the residuals’ scatter plots, together with the 
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goodness of fit measures incorporated in the software (including the Akaike 
and Schwartz criteria). 
 
7. Simulation of tapentadol (TAP) dosage regimens 
A compartment open pharmacokinetic model was used to simulate the 
concentration–time profile for several dosage regimens after IM 
administration. Based on the pharmacokinetic analysis of pooled data, 
computer simulations (WinNonlin 5.3) were performed to calculate 
intramuscular dosage regimens that maintain TAP plasma concentrations 
greater than the minimal effective concentration (MEC) in human (148 
ng/mL) for roughly 50% of the dose interval.  
 
8. Statistical analysis 
Pharmacokinetic data were evaluated using ANOVA tests to determine 
statistically significant differences. The pharmacokinetic parameters are 
presented as means ± standard deviation (SD) and the TAP plasma 
concentrations of each cat are presented as means. All analyses were 
conducted using GraphPad InStat (GraphPad Software). In all experiments, 
differences were considered significant if P < 0.05. 
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III. Results 
After IV administration, some adverse effects including salivation, 
agitation and panting, were noted in all cats. However, they resolved rapidly 
and spontaneously within 20 min. These adverse effects were also detected 
after IM and SC administration, but were less intense and of a shorter 
duration. It was occurred in four cats (3/6 IM; 1/6 SC). 
 
1. Validation of bioanalytical method 
The HPLC method used was re-validated in feline plasma. Briefly, 
TAP was linear (r2 > 0.98) in the range 10–4000 ng/mL. The intra-day 
repeatability was measured using coefficients of variation and was < 7.3%. 
Accuracy was measured by measuring proximity to the concentration added 
on the same replicates and was < 5.3%. 
 
2. Pharmacokinetics of tapentadol (TAP) 
In all three-administration groups, TAP concentrations were detectable 
in the plasma for up to 8 h. Some variability in plasma drug concentrations 
was detected among the cats and groups. Fig. 1 and 2 show individual (A–F) 
and average TAP plasma concentrations vs. time curves after each 
administration route, respectively. After IM injection, TAP showed variable 
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but fast absorption (Tmax = 0.25 h, range 0.08–0.75 h), while after SC 
administration, absorption was significantly slower (Tmax = 0.63 h). The T1/2 
λz was quite similar between the three administration routes in the range of 
about 2–3 h. Also Vz/F and Cl/F values were constant among the treatment 
groups. In the elimination phase of the curve, the decline of TAP was linear 
without any evidence of a secondary peak. The average pharmacokinetic 
parameters calculated for the three administrations are reported in Table 1. 
The bioavailabilities were almost complete, accounting for 94% and 90% 
after IM and SC administrations, respectively. 
 
3. Simulation of tapentadol (TAP) dosage regimen 
After pharmacokinetic simulation of IM multiple dosing, it was found 
that the plasma concentration when the TAP is administered at 5mg/kg q 24h 
is insufficient to exceed the MEC for 12 h (50% of dose interval). Following 
simulations of IM administration of TAP at doses of 3 mg/kg TID and 5 
mg/kg BID, plasma concentrations were greater than the MEC value of 148 
ng/mL for over 4.5 and 6 h, respectively (Fig. 3).  
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Fig. 1. Individual plasma concentration vs. time semilogarithmic curves (A–
F) of tapentadol (TAP) after a single IV (circles), IM (squares) or SC 
(triangles) administration (n = 6). 
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Fig. 2. Mean plasma concentration vs. time semilogarithmic curves of 
tapentadol (TAP) after a single IV (circles), IM (squares) or SC (triangles) 
administration (n = 6). The horizontal dotted line shows the minimal 
effective concentration (MEC, 148 ng/mL) reported for humans and its 
intercepts with the concentration vs. time curves reported in this feline study. 
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Fig. 3. Mean plasma concentrations vs. time curves of tapentadol (TAP) 
following a simulated IM multiple dose rate at 5 mg/kg BID (dotted line) and 
a simulated PO multiple dose rate at 3 mg/kg TID (solid line). The dashed 
line represents the minimal effective concentration (MEC; 148 ng/mL) in 
humans. 
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Table 1. Pharmacokinetic parameters after injection of tapentadol (TAP) at 5 
mg/kg by IV, IM and SC route, respectively in cats (n = 6) 
Phamacokinetic  
parameters (Unit) 
IV  
(Mean±SD) 
IM  
(Mean± SD) 
SC  
(Mean± SD) 
 λz (1/h) 0.25±0.07 0.34±0.11 0.37±0.12 
 T1/2λz (h) 2.93±0.86 2.28±0.85 2.05±0.6 
 Tmax (h) -   0.25±0.26 a       0.63±0.31 a, b 
 Cmax (ng/mL) -  1406±779 a      906±356 a, b 
 C0 (ng/mL) 6289±1906 - - 
 AUCo-∞ (h ng/mL) 2423±533 2245±343 2202±611 
 Vz/F (mL/kg) 8.79±1.97 7.53±2.95 7.06±2.10 
 Cl/F (mL/min/kg) 35.60±7.05 37.85±5.68 40.13±9.97 
 MRT (h) 2.44±0.87 2.55±0.94 2.35±0.34 
 F (%) - 93.93±9.91  90.01±6.52 a 
λz, first-order rate terminal elimination constant; T1/2λz, half-life of the 
terminal portion of the curve; Tmax, time at the maximum drug concentration; 
Cmax, maximum drug plasma concentration; C0, concentration at time 0; 
AUC0−∞, area under the curve from 0 to infinity; Vz/F, volume of 
distribution during the elimination phase; Cl/F, body clearance during the 
elimination phase; MRT, mean residence time; F%, bioavailability. 
a, P < 0.05 versus IV administration group. 
b, P < 0.05 versus IM administration group. 
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IV. Discussion 
The side effects of TAP demonstrated in this study were very similar to 
those previously reported in dogs. However, cats became agitated, while 
dogs demonstrated depression (Giorgi et al., 2012a). This concurs with the 
contrasting behavior reported in cats and dogs after morphine administration 
(KuKanich and Papich, 2009). The side effects were more severe and of 
longer duration following IV than IM and SC administrations. This is most 
likely to be the result of high plasma drug concentrations achieved by the IV 
route of administration. None of the cats in this study vomited, which is a 
well-known side effect of morphine in cats (Taylor et al., 2001). Although an 
injectable pharmaceutical form of TAP is not currently available for 
purchase, the dose administered in the present study appears high when 
compared to the dose used in human clinical therapy (200 mg/patient PO). It 
is likely that the relative dose used for cats is even higher if the low oral 
bioavailability in humans is taken into account (30%; Xu et al., 2010). 
However, the same dose rate was effective for pain relief in rabbits and 
turtles (McMillan et al., 2008; Chapter 3). Indeed, it is similar to the 
injectable dose of tramadol tested in dogs (Giorgi et al., 2010). Since the side 
effects of TAP are dose-related in dogs (Giorgi et al., 2012a) and humans 
(Kleinert et al., 2008), a lower dose rate might reduce the adverse effects in 
cats. 
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The present study is the first pharmacokinetic study of TAP in cats, 
although the use of TAP in dogs has been recently considered (Giorgi, 2012). 
An initial pharmacokinetic study in dogs has suggested its prospective use as 
an injectable rather than oral drug, because of its very low oral 
bioavailability (Giorgi et al., 2012a). Another study by the same group has 
confirmed its efficacy as a pain reliever, as well as its good safety profile in 
rabbits after IV administration (Giorgi et al., 2013). In chapter 3, TAP 
produced the effective antinociception and the onset of the analgesic effect 
was rapid in turtles. To the authors’ knowledge, there are no published 
reports of the pharmacokinetics and pharmacodynamics of this drug in cats 
thus far. Drug dosing schedules for the cat are often extrapolated from other 
species, despite evidence that cats metabolise some drugs uniquely (Boothe, 
1990). 
Both plasma concentrations and the pharmacokinetic data reported 
here show some inter- and intra-cat variation, in agreement with previous 
studies of opioids (Taylor et al., 2001). The use of cats of widely varying 
ages and both genders might have affected the results of our study. However, 
statistically significant associations between pharmacokinetic data and cat 
age or gender were not found, although a larger sample size might be helpful 
in verifying this point. Individual cat variability might be relevant in clinical 
practice where animals are often highly variable both in signalment, and 
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health. The plasma drug concentrations after IV administration were similar 
to those detected after the same IV dose in rabbits (Giorgi et al., 2013). 
Conversely, the period of TAP detection in plasma was longer than those 
reported for dogs (6 h; Giorgi et al., 2012a), rabbits (4 h; Giorgi et al., 2013) 
and goats (6 h; Chapter 2), despite the dose rates being lower than or equal to, 
respectively, the dose rate used in the present study. This is to be expected, 
as the T1/2λz reported in this study was longer than those previously used for 
dogs, rabbits and goats (dogs, approximately 1 h, Giorgi et al., 2012a; rabbits, 
0.52 h, Giorgi et al., 2013, 1.2 h, Chapter 2). Glucuronidation is the main 
metabolic pathway for TAP in humans, as 83% of an oral dose of TAP is 
converted to and excreted as an inactive glucuronidated metabolite. Cats 
have very limited UDP-glucuronyltransferase activity (Court and Greenblatt, 
1997), which might explain the inter-species differences in T1/2λz values. 
However, the elimination of half-life in turtles (4 h) was longer than that 
used for cats (Chapter 3). It might be explain that the metabolic rate of 
mammals is faster than that of reptiles (Berner, 1999). 
The IM and SC bioavailability reported in this study was TAP in cats is 
relatively high and is in line with previous study of TAP in goats (Chapter 2). 
Moreover, this agrees with what is published for other classical (Barnhart et 
al., 2000; Taylor et al., 2001) and atypical (Giorgi et al., 2009) opioid drugs. 
Despite the lower mean Cmax obtained after SC administration, the difference 
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in bioavailability compared to IM administration was not significant. Indeed, 
SC administration appeared to produce something similar to a depot effect, 
releasing the drug more slowly than after IM administration. This effect was 
especially appreciable in the pharmacokinetic curves from individual cats, 
which showed extended TAP elimination phases (although not significantly) 
and increased AUC values. This pharmacokinetic feature might also explain 
the lower number of adverse effects reported in the SC group. 
In humans, the minimal effective concentration (MEC) is 0.67 µM/L, 
which is equivalent to 148 ng/mL (Tzschentke et al., 2007). If the human 
MEC was applied to the cat, the plasma drug concentration reported in the 
present study exceeded this value for over 3 h (Fig. 2). However, 
extrapolation of the MEC value from humans to animals might not be 
advisable and caution should be given (Giorgi and Yun, 2012). It is also 
recognized that there could be some discrepancy between plasma 
concentration and the actual effect at the receptor level (Toutain and Lees, 
2004). Indeed, TAP was recently reported to be effective in rabbits for at 
least 10 h after a 5 mg/kg IV administration (Giorgi et al., 2013), although 
TAP concentrations were below the human MEC after 2 h, suggesting that 
TAP produces a long lasting effect. 
The plasma concentration of TAP calculated after the simulation is 
exceeded for over 4.5 and 6 h, after 3 mg/kg TID and 5 mg/kg BID, 
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respectively. However, the dose regimen of TAP at 5 mg /kg BID is likely to 
produce more severe side effects than those reported in this study following a 
single injection, although the side effects in this study were transient. 
Administering TAP IM three times a day at 3 mg/kg might be a good 
compromise in terms of amount of drug administered and interval of 
administration. However, parameters such as onset time and time exceeding 
the MEC should be verified with further appropriately conducted 
pharmacokinetic/pharmacodynamic studies to clarify this. 
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Chapter 2. Pharmacokinetics of Tapentadol (TAP) after Intravenous 
(IV) and Intramuscular (IM) Administration in Goats (Capra hircus) 
 
Abstract 
The objective of the present study was to assess the pharmacokinetics 
of the novel atypical drug tapentadol (TAP) after intravenous (IV) and 
intramuscular (IM) injections in normal goats. A 2 x 2 cross over design 
study design was carried out. Each goat was given 5 mg/kg body weight of 
TAP by IV and IM routes. The concentrations of TAP in plasma were 
evaluated using HPLC. Transient adverse effects (tremors and ataxia) were 
noticed in some animals, especially after IV administration. The plasma 
concentrations vs. time course after the two administrations were fitted using 
a bi-compartmental model. After IM injection, TAP showed a very fast 
absorption (Tmax = 0.17 h). The average volume of distribution and clearance 
after IV and IM administration were 4387 ± 1935 and 4076 ± 1082 mL/kg, 
and 4449 ± 1134 and 6328 ± 1351 mL h/kg, respectively. The IM 
bioavailability was quite high, despite being variable (87.78 ± 35.63%). In 
conclusion, TAP showed a short half-life, thus intravenous infusion rather 
than multiple daily administrations or a bolus might be more suitable in this 
animal species. However, it is premature to recommend the use of this drug 
in clinical practice. 
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I. Introduction 
Opioids are widely used for treatment of pain in human and veterinary 
medicine, and are considered to be the prototypical class of analgesics (Fox, 
2010). It is used in veterinary medicine not only for analgesia, but also in 
many other clinical applications (e.g. antitussive, antidiarrheal, emetic). A 
significant drawback of opioids is that they are generally controlled 
substances (Pascoe, 2000; Clutton, 2010) and have serious potential adverse 
effects (Vadivelu et al., 2011). Furthermore, prolonged treatment with many 
opioids may induce tolerance to their analgesic effects, meaning that long-
term therapy with opioids must be carefully monitored and frequently 
increased to maintain a clinically satisfactory analgesic effect (Dickenson & 
Suzuki, 2005). It would therefore be useful to have alternative drugs 
available to control pain in animals. 
The use of most opioid drugs in goats is off-label as most of these 
active ingredients are not approved for this species. Although extra-label use 
of approved drugs by veterinarians is common in the slightly less routine 
domestic species, there is minimal information on drug pharmacokinetics, 
which would be useful for determining appropriate drug dosages. For this 
reason, some opioid drugs such as tramadol (De Sousa et al., 2008), 
buprenorphine (Ingvast-Larsson et al., 2007) and methadone (Olsen et al., 
2013) have been tested in goats. Tramadol and buprenorphine appear to be 
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unsuitable in this species because of the lack of production of the active 
metabolite (and hence efficacy) and the severe adverse effects, respectively. 
In regards to methadone, basic information only is available presently. 
Although it has a better safety profile compared to buprenorphine, it still 
retains some side effects and the short half-life, limiting its prospective use 
in combinational pain relief therapy (Olsen et al., 2013). 
TAP is a novel analgesic opioid drug that is unusual in its possession 
of a dual mechanism of action (MOR agonist and NE reuptake inhibitor). As 
for tramadol, this feature makes the active ingredient an attractive potential 
progenitor of a new pharmacological class and a prospective drug for use in 
veterinary medicine (Giorgi, 2012). 
TAP was launched on the European market for human use in 2011. 
TAP in humans has shown a lower incidence of adverse effects compared to 
equianalgesic doses of morphine (Kleinert et al., 2008) and oxycodone 
(Etropolski et al., 2011). This active ingredient has attracted the attention of 
the veterinary world because its MOR affinity is 50-fold lower than that of 
morphine but 120-fold higher that tramadol (Giorgi, 2012). Additionally, its 
second synergistic mechanism of action does not involve 5-HT reuptake, 
reducing the possibility of the “serotonin storm effect” reported following 
rapid IV tramadol injections. In brief; i) TAP is recommended in cases of 
moderate to severe pain (similar to morphine); ii) compared to morphine, 
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TAP produces much less nausea and vomiting and when these effects are 
present, their duration is shorter (Tzschentke et al., 2009); iii) this drug is not 
restricted/regulated in most European countries; iv) it does not require 
metabolic activation to be effective and variation in drug metabolism should 
not widely affect its efficacy. 
Very few studies have been carried out in the veterinary field thus far. 
The pharmacokinetic features of TAP have been investigated in dogs after 
intravenous and oral administration, showing a very low oral bioavailability 
(4%) (Giorgi et al., 2012a). In rabbits undergoing castration, IV TAP was 
shown as having an excellent efficacy in reducing intra/post surgery pain 
(Giorgi et al., 2013). In cats, IV, IM and SC administration of TAP showed 
similar pharmacokinetic profiles (Chapter 1). In turtles, IM injection of TAP 
produced an effective antinociception against the thermal stimuli (Chapter 3). 
The side effects in these animal species have been reported as minor and 
transient. 
The aim of the present research was to assess the pharmacokinetics of 
TAP after intravenous (IV) and intramuscular (IM) injection in normal goats. 
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II. Materials and Methods 
1. Drugs and reagents 
Pure powder (> 99.8% purity) of TAP hydrochloride was purchased 
from Bepharm Ltd. Pure powder (> 99.8% purity) of M1, used as internal 
standards (IS), was obtained from LCG Promochem. HPLC grade 
acetonitrile (ACN), dichloromethane (CH2Cl2) and diethyl ether (Et2O) were 
purchased from Scharlau. Analytical grade acetic acid and sodium 
tetraborate decahydrate were obtained from BDH (Dublin, Ireland). HPLC 
grade water was obtained by distilling deionised water produced by a Milli-
Q Millipore Water System (Millipore, Milan, Italy). All the other reagents 
and materials were of analytical grade and supplied from commercial sources. 
The injectable solutions were prepared by dissolving the pure TAP 
hydrochloride powder in saline to give a 5 mg/mL solution, which was then 
passed through a 0.45 µm filter, maintaining sterile conditions. 
 
2. Animals 
Six local Nubian dry non-pregnant female goats, aged between 3-8 
years, with a body weight of 52-72 kg, were used. The goats were previously 
determined to be clinically healthy on physical examination, serum 
chemistry and haematological analyses. Animal care and handling was 
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performed according to the provision of the EC council Directive 86/609 
EEC as well as according to Institutional Animal Care and Use directives 
issued by the Animal Welfare Committee of the Robert H. Smith Faculty of 
Agriculture, Food and Environment, Hebrew University of Jerusalem that 
approved the study protocol. 
 
3. Experimental design 
Goats were randomly assigned to two treatment groups. An open, 
single-dose, two-treatment, 2×2 cross over design was used. Two groups of 
goats (n = 3) were housed in open pens with dirt floors (3.5×3.5 m2) at the 
Faculty facility. The drug was administrated in a single-dose fashion via 
either the IV (group I) or IM (group II) routes. All goats were fasted 
overnight before the experiment. In the first period, each goat in group I 
received a single IV dose of TAP solution (5 mg/mL) at 5 mg/kg injected 
slowly over 2 minutes into the left jugular vein. This dose was selected based 
on previous information describing the effectiveness of TAP in laboratory 
species (Giorgi et al., 2013). The other group (II) received a single IM 
injection of 5 mg/kg of TAP given into the rectus femoris portion of the 
quadriceps femoris muscle. An interval of 1 week (wash out period) was 
observed, to ensure complete metabolism and excretion of TAP. After this 
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period the groups were rotated and the experiment was repeated. By the end 
of the study each goat had received TAP by both administration routes. 
A catheter was placed into the right jugular vein to facilitate blood 
sampling. Blood samples (2.5 mL) were collected at 0.08, 0.25, 0.5, 0.75, 1, 
1.5, 2, 4, 6, 8 and 10 h after administration of TAP, and placed in an ice bath 
in collection tubes containing lithium heparin. All blood samples were 
centrifuged within 30 min of collection, at 3,000×g, 4°C for 15 min to 
separate plasma. Harvested plasma was stored at -70 °C until analysis which 
occurred within 15 days of collection. 
 
4. High performance liquid chromatography (HPLC) 
The concentrations of TAP in plasma were evaluated using HPLC, 
according to the method previously described by Giorgi et al. (2012b). The 
analytical method was briefly re-validated in plasma from the goats. The 
HPLC system was an LC Waters (Waters, USA) consisting of quaternary 
gradient system (600 Controller, Waters, USA), in-line degasser (model AF, 
Waters, USA), photodiode array detector (2998 model, Waters, USA), multi 
lambda fluorescence detector (model 2475, Waters, USA) and autosampler 
(model 717 plus, Waters, USA). Data was processed using Empower ProTM 
software (Waters, USA). The chromatographic separation assay was 
performed with a SunFire C18 analytical column (150x4.6 mm inner 
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diameter, 5 µm particle size, Waters) maintained at 25 °C. The mobile phase 
consisted of ACN (A): 0.2% acetic acid (B) at a flow rate of 1 mL/min. 
Excitation and emission wavelengths were set at 273 and 298 nm, 
respectively. The linear gradient elution system was performed as follows; 5-
95% B (0-20 min), 95-5% B (20-25 min) and finally 5% B isocratically (25-
32 min). 
 
5. Preparation of plasma samples 
Briefly, 50 µL of IS solution (0.5 µg/mL) and 0.2 mL 0.2 M borate 
buffer adjusted to pH 9.3 were added to a 1.5 mL polypropylene snap cap 
tube (Sarsedt, USA) containing 0.5 mL of plasma. After vortex-mixing, 0.4 
mL of extraction solvent (Et2O:CH2Cl2 7:3 v/v) was added, the tube was then 
vortexed (30 sec) and shaken for 5 min and then centrifuged for 10 min at 
15,625×g. 0.3 mL of the organic layer was transferred into a clean 0.5 mL 
polypropylene snap cap conical tube, vortexed and shaken with 0.2 mL of 
back-extraction solvent (0.05 M HCl:ACN 1:1 v/v) for 5 min and centrifuged 
for 10 min at 15,625×g. The aqueous phase (50 µL) was injected onto the 
HPLC system. 
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6. Pharmacokinetic evaluation 
The measured plasma concentrations of TAP were plotted versus time 
for each goat and data were analysed using a commercially available 
software program (Win Nonlin 5.3, Pharsight Corporation, Mountain View, 
CA, USA). For each data set, a compartmental approach was carried out 
(Gabrielsson & Weiner, 2002). Different models were assessed by visual 
inspection of the curve fits and the residuals’ scatter plots, together with the 
goodness of fit measures incorporated in the software (including the Akaike 
and Schwartz criteria).  
Maximum concentration (Cmax) of TAP in plasma, and the time 
required to reach Cmax (Tmax) were predicted from the data. The 
concentration at time 0 (C0) in the IV administration samples is estimated by 
back-extrapolating from the first two concentration values. The area under 
the concentration vs. time curve (AUC0-∞) was calculated using the linear 
trapezoidal rule. The IM bioavailability (F%) was calculated from the ratio 
of the areas under the plasma TAP concentration curve, after IM and IV 
administration, indexed to their respective dose:  
F (%) = (AUCIM x DoseIV)/(AUCIV x DoseIM) x 100 
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7. Simulation of tapentadol (TAP) dosage regimens 
Based on the pharmacokinetic analysis of pooled data, computer 
simulations (WinNonlin 5.3, Pharsight Corporation, Mountain View, CA, 
USA) were performed to determine intramuscular dosage regimens that 
maintain TAP plasma concentrations greater than the minimal effective 
concentration (MEC) in human (148 ng/mL) for roughly 50% of the dose 
interval.  
 
8. Statistical analysis 
Pharmacokinetic data were evaluated using the ANOVA test. 
Correlations between the value groups were carried out by Pearson’s test. 
The results were presented as means ± standard deviation (SD). All analyses 
were conducted using GraphPad InStat (GraphPad Software). In all 
experiments, differences were considered significant if the associated 
probability level (P) was lower than 0.05. 
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III. Results 
About three-four minutes after IV administration, some adverse effects 
including tremors and ataxia were noticed in two goats. However, they 
resolved rapidly (10 min) and spontaneously. These adverse effects were not 
detected after IM dosing. Three days after drug administration severe hair 
loss was noticed in goats from both groups. This effect was less intense in 
the group administered with IM injection. 
 
1. Validation of bioanalytical method 
The HPLC method was re-validated in the goat plasma. Briefly, TAP 
was linear (r2 value > 0.98) in the range 5-5000 ng/mL. The intraday 
repeatability was measured as coefficient of variation and was lower than 
8.2%, whereas accuracy, was lower than 6.1%. 
 
2. Pharmacokinetics of tapentadol (TAP) 
A bi-compartmental model best described the data set of all the 
animals in both groups. In both the groups, TAP concentrations were 
detectable in the plasma for up to 6 h. Some variability in drug plasma 
concentrations was detected among the subjects, especially in the terminal 
part of the curve. Fig. 1 and 2 report the single (A-F) and average TAP 
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plasma concentrations vs. time curves after the two administrations, 
respectively. After IM injection, TAP showed a very rapid absorption (Tmax 
= 0.17 h). The average values of T1/2β after both administrations were quite 
different, but the large variability reported after the IV administration 
resulted in this difference being insignificant. In addition, Vd and Clt values 
were constant between the treatment groups. The average pharmacokinetic 
parameters calculated for the two administrations are reported in Table 1. 
The IM bioavailability (F%) was high, although variable, reaching average 
level of 88%. 
 
3. Simulation of tapentadol (TAP) dosage regimen 
A compartmental open pharmacokinetic model was fitted to the pooled 
data from six goats, and the model was used to simulate the concentration–
time profile for several dosage regimens after IM administration (5 mg/kg 
BID; 2 mg/kg TID and 2.5 mg/kg TID). The best model included absorption 
term and biexponential decay. 
Parameters of this average model were V1_F, K01, K10, K12 and K21 
which were 3131 ± 543 (mL/kg), 49.04 ± 10.82 (1 /h), 1.84 ± 0.21 (1/h), 
1.41 ± 0.36 (1/h) and 2.28 ± 0.56 (1/h), respectively. Following simulations 
of IM administration of TAP at a dose of 2.5 mg/kg q 8h, plasma 
concentrations were greater than the MEC value of 148 ng/mL for 
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approximately 1 h (Fig. 3). Simulation of IM administration of TAP at doses 
of 5 mg/kg BID gave drug concentrations exceeding the MEC for over 2 
hours. This simulation was disregarded because the large dose of opioid drug 
could intensify the side effects reported in this study. Simulations with 
greater than three administrations per day were not attempted because of the 
associated difficulty in managing such regimes in non-hospitalized animals. 
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Fig. 1. Individual concentration vs. time curves (A-F) of tapentadol (TAP)  
(5 mg/kg) after single IV (-●-) and IM (--○--) administrations in goats. 
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Fig. 2. Mean concentration vs. time curves of tapentadol (TAP) (5 mg/kg) 
after single IV (-●-) and IM (--○--) administrations in goats (n = 6). 
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Fig. 3. Simulated average pharmacokinetic profile of plasma levels of 
tapentadol (TAP) after IM administration at 2.5 mg/kg TID in the goat. The 
horizontal dashed line indicates the MEC reported in humans (Tzschentke et 
al., 2007). 
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Table 1. Main average pharmacokinetic parameters after injection of 
tapentadol (TAP) at 5 mg/kg by IV, and IM route, respectively in goats (n = 
6) 
Pharmacokinetic 
Parameters (Unit) 
IV IM 
Mean SD Mean SD 
A (ng/mL) 1639.74 2098.90 2682 3241 
α (1/h) 3.80 4.90 3.13 1.52 
B (ng/mL) 291 229 301 195 
β (1/h) 0.44 0.39 0.61 0.23 
k12 (1/h) 1.47 2.24 0.91 0.64 
k21 (1/h) 0.99 0.90 1.21 0.74 
kel (1/h) 1.78 2.27 1.62 0.39 
ka (1/h) NA NA 17.30 14.37 
t1/2α (h) 0.37 0.20 0.27 0.14 
t1/2β (h) 3.22 3.27 1.29 0.54 
t1/2ka (h) NA NA 0.06 0.04 
Tmax (h) NA NA 0.17 0.07 
Cmax (ng/mL) NA NA 898 350 
C0 (ng/mL) 1931 2274 NA NA 
AUCo-∞ (ng/mL·h) 1186 298 804 123 
Vd (mL/kg) 4387 1935 4076 1082 
Clt (mL h/kg) 4449 1134 6328 1351 
F (%) NA NA 87.78 35.63 
A, intercept for the distribution phase; α, distribution slope; B, intercept for the 
elimination phase; β, elimination slope; k12, rate of movement from compartment 1 
to 2; k21, rate of movement from compartment 2 to 1; kel, rate of elimination; ka, rate 
of absorption; t1/2α, the distribution half-life; t1/2β, the elimination half-life; t1/2ka, 
absorption half-life; Tmax, time of peak concentration; Cmax, peak plasma 
concentration; C0, concentration at time 0; AUCo-∞, area under the curve from time 
zero to infinity; Vd, apparent volume of distribution of the area; Clt, total body 
clearance; F, bioavailability; NA, not applicable. 
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IV. Discussion 
The side effects shown in this study were very similar to those 
previously reported in dogs administered with TAP (Giorgi et al., 2012a). 
The adverse effect profile concurs also with those reported in ruminant 
species after the administration of the atypical opioid tramadol (Giorgi et al., 
2010; Cox et al., 2010). Side effects such as itching (due to histamine 
release), climbing, scratching, tail-flicking, and gnawing common in goats 
after administration of classical opioid drugs (Olsen et al., 2013; Ingvast-
Larsson et al., 2007), were absent during the study. This difference might be 
due to the lower affinity of TAP at the MOR as compared to classical opioids 
(Giorgi, 2012). However, severe hair loss was noticed. As hair loss has never 
been reported in dogs, rabbits, cats and humans following TAP 
administration, it might be due to an unusual sensitivity of goats to this 
active ingredient. However, the pathogenesis of this response is unknown at 
this stage, further investigations are needed in small ruminant species to 
clarify this issue. 
The present is the first pharmacokinetic study of TAP in goats. The use 
of TAP in veterinary medicine has been recently considered (Giorgi, 2012) 
and previous study has confirmed its efficacy as an analgesic, as well as its 
attractive safety profile in rabbits after IV administration (Giorgi et al., 2013). 
There is no data on the pharmacokinetics and pharmacodynamics of this 
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drug in ruminants thus far. Dosing schedules in the goat are often 
extrapolated from other species, however the extrapolation of 
pharmacokinetic profiles obtained in one species to another could be 
misleading (Szotáková et al., 2004). 
Theoretically the rational for the use of TAP in ruminants that this 
active ingredient might bypass the shortcomings normally associated with 
other atypical opioids. Additionally, other reasons may be: (1) the full 
analgesic activity of TAP is contained within a single molecule (no 
enantiomers with different activities that could influence its analgesic and 
tolerability profile); (2) only the parent compound is involved in its 
pharmacological activity (i.e. no metabolic activation is necessary) 
(Terlinden et al., 2010); (3) the time dependent changes in the dynamic of 
opioid and monoaminergic analgesia occur in parallel (Schroder et al., 2011); 
(4) no CYP450 induction/inhibition exists which could negatively affect 
analgesia (Terlinden et al., 2007); (5) the 5HT reuptake inhibition triggering 
of adverse effects is negligible (Schiene et al., 2011). 
Both, plasma concentrations and the pharmacokinetic data show some 
inter- and intra-subject variation, in line with previous studies on opioids 
(Ingvast-Larsson et al., 2007; Olsén et al., 2013). This variation might have 
been exacerbated by the wide age range of animals used in this study. 
However, the variations did not appear to be associated with age, although a 
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larger sample size of animals and inclusion of male animals would be needed 
to clarify this issue. This pattern might be relevant in clinical practice where 
patients are often highly variable both in signalment and health. The drug 
plasma concentration profile after IV administration was similar to that 
detected in dogs (Giorgi et al., 2012a). Conversely, the period of TAP 
detection in plasma was longer if compared to that reported in rabbits (4 h; 
Giorgi et al., 2013) administered IV with the same dose used in the present 
study. The IM bioavailability was large and it is in line with previous study 
of TAP in cats (Chapter 1). Moreover, this is in line with other IM 
bioavailabilities reported for both classical (Ingvast-Larsson et al., 2007) and 
atypical (Giorgi et al., 2010; Cox et al., 2010) opioid drugs. 
In humans the minimal effective concentration (MEC) of TAP is 
reported to be 0.67 µM/L, which is equivalent to 148 ng/mL (Tzschentke et 
al., 2007). If the human MEC is assumed to apply also in the goat, the 
plasma drug concentration reported in the present study after IM or IV 
injection of TAP at 5mg/kg exceeds this value for over 2 hours. However, 
extrapolation of the MEC value from human to animals might not be 
completely advisable and caution should be used (Giorgi & Yun, 2012). 
Multiple daily doses of TAP at 5 mg/kg administration are likely to 
produce more severe side effects than those reported in this study following a 
single injection. Additionally TAP is an opioid drug with an unknown safety 
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profile in goats and caution in dosing should be used. Administering TAP IM 
three times a day at 2.5 mg/kg gives plasma concentrations over the MEC for 
at least 1 h. This regime might be a good compromise in terms of amount of 
drug administered and interval of administration. Nevertheless, from the 
perspective of PK, 1 hour seems too short a time to maintain adequate 
plasma concentrations for pain relief. However, parameters such as MEC and 
efficacy should be verified with appropriate pharmacokinetic-
pharmacodynamic studies, and further studies are needed to clarify this issue. 
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Chapter 3. Pharmacokinetic/Pharmacodynamic Assessments of 
Tapentadol (TAP) in Yellow-Bellied Slider Turtles (Trachemys 
scripta scripta), After a Single Intramuscular (IM) Injection 
 
Abstract 
In reptiles, administration of opioid drugs has yielded unexpected 
results with respect to analgesia. Tapentadol (TAP) (Giorgi, 2012) is a novel 
atypical opioid drug labeled for human use. The aim of this study was to 
evaluate the pharmacokinetics and the pharmacodynamics of this drug in 
yellow-bellied slider, after a single intramuscular injection of 5 mg/kg of 
TAP. TAP plasma concentrations were determined by a validated HPLC-FL 
method, while an infrared thermal stimuli was applied to the plantar surface 
of the turtles’ hind limbs to evaluate the thermal withdrawal latency (TWL) 
(Riviere et al., 1997). 
TAP plasma concentrations were detectable between 1-24 h. The TAP 
treated group showed an increase in TWL 1 hour after drug administration 
(13.32 ± 6.40 s). Subsequently, TWL decreased with time, significant 
differences between treatment and control groups were apparent up to 10 h 
following treatment. A linear relationship (r2 = 0.99) between TAP plasma 
concentration and effect was found. Given these findings, TAP appears to be 
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an attractive option for antinociception in turtles, due to its rapid onset and 
acceptable duration of effect. 
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I. Introduction 
Veterinary medicine faces the unique challenge of having to treat many 
animal species, including mammals, birds, reptiles and fish. The main 
challenge for veterinarians is not just to select a drug but to determine, for 
the selected agent, a rational dosing regimen. Determining this is a long and 
complicated endeavour because of differences in the expression of enzymes, 
receptors and signal transduction molecules between species (Giorgi, 2012). 
Both inter- and intra-species differences in drug response can be accounted 
for as either being due to variations in drug pharmacokinetics (PK) or drug 
pharmacodynamics (PD), the magnitude of which varies from drug to drug 
(Riviere et al., 1997). Hence, PK/PD studies are critical when a drug is 
applied to a new animal species. 
Nowadays we are far more cognisant of pain in animals. Animal 
species that years ago were considered wild animals are now pets and owners 
expect an adequate level of care to be provided. This change in attitude has 
resulted in a push for the development of more effective and innovative 
veterinary therapies (Giorgi and Owen, 2013; Giorgi et al., 2012b; Giorgi 
and Yun, 2012). With the increasing popularity of herpetoculture, there is 
more information on associated diseases and treatment options are being 
investigated, starting with the classes of drugs that have proven efficacy in 
other species. This research has emphasized the inaccuracies that result when 
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the effects and consequences of drugs for the species of interest are predicted 
based on extrapolation from other species which have marked differences in 
their physiology (Riviere and Papich, 2013). 
Opioids are considered the most effective drugs for controlling pain in 
mammals (Egger et al., 2013). In reptiles, opioid drug administration has 
yielded unexpected results with respect to analgesia. Butorphanol does not 
change thermal withdrawal latencies (TWL) in red-eared slider turtles 
(Trachemys scripta elegans) (Sladky et al., 2007) and bearded dragons 
(Pogona vitticeps) (Sladky et al., 2008) or thermal thresholds in green 
iguanas (Iguana iguana) (Fleming and Robertson, 2012). Buprenorphine did 
not alter responses to a noxious electrical stimulus administered to green 
iguanas (Greenacre et al., 2006) and did not provide an analgesic effect in 
red-eared slider exposed to a noxious thermal stimulus (Christoph et al., 
2012). Morphine increased TWL in red-eared slider (Sladky et al., 2007) and 
bearded dragons (Sladky et al., 2008) at doses ranging between 1.5 and 20 
mg/kg, but was ineffective at doses up to 40 mg/kg in corn snakes (Sladky et 
al., 2008). In contrast, the atypical opioid tramadol, whose use in mammals 
has been widely questioned (Giorgi et al., 2009a; 2009b; 2012c), has proven 
to provide antinociception (10 mg/kg SC) for at least 48 hours following 
administration in red-eared slider (Baker et al., 2011). Tramadol produces 
MOR activation (6000 times less than morphine) as well as inhibition of 
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serotonin (5HT) and norepinephrine (NE) reuptake in mammals. It has been 
shown that the analgesic efficacy of tramadol is mediated by the M1 
metabolite (200-300 times more potent on MOR activation than the parental 
compound) (Raffa et al., 1992). 
Tapentadol (TAP) is a novel atypical opioid drug labeled for human 
use. Based on its unique mechanism of action, it has been proposed as the 
first representative of a new pharmacological class of centrally acting 
analgesics: the MOR agonist, NE reuptake inhibitors (MORNRI) (Giorgi, 
2012). Interestingly, even though its MOR affinity is 50-fold lower than that 
of morphine it has shown an equivalent analgesic activity. Additionally, after 
systemic administration in humans it is associated with a 2-3-fold reduction 
in the rate of adverse effects reported with oxycodone (Biondi et al., 2013). 
This finding, consistent across different pain relief evaluation models, may 
be due to a better brain penetration of TAP, but also suggests that the NE 
reuptake-inhibitory property, contributes to a more potent analgesia that 
would be expected solely from its MOR agonism (Tzschentke et al., 2006). 
If the reduction in adverse effects observed in humans holds true in reptiles, 
TAP would be an interesting analgesic. The objective of this study is to 
begin studying this promising molecule by assessing the PK/PD in yellow-
bellied slider, after a single intramuscular injection of TAP. 
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II. Materials and Methods  
1. Drugs and reagents 
TAP hydrochloride was supplied as a pure powder (> 99.8% purity; 
Bepharm). M1, the metabolite of tramadol, was used as an internal standard 
and supplied as pure powder (> 99.8% purity; LCG Promochem). 
Additionally, high-performance liquid chromatography (HPLC) grade 
acetonitrile (ACN), dichloromethane (CH2Cl2) and diethyl ether (Et2O) were 
used in the assays (Scharlau, USA). Acetic acid and sodium tetraborate 
decahydrate (BDH, Ireland) were of analytical grade. HPLC grade water was 
obtained by distilling deionized water produced by a Milli-Q Millipore water 
system (EDM Millipore, Italy). All the other reagents and materials were of 
analytical grade and supplied from commercial sources. The injectable TAP 
solutions were freshly prepared by dissolving the pure TAP hydrochloride 
powder in saline to produce a 5 mg/mL solution, which was then passed 
through a 0.45 µm filter, maintaining sterile conditions. 
 
2. Animals 
Seven female and two male of turtles (Trachemys scripta scripta), with 
body weights ranging from 0.5 to 1.3 kg, supplied by a local park, were used 
for the study. Turtles were acclimated for a 2-week period prior to 
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commencement of the study. Turtles were judged to be in good health based 
on physical examination at the time of acquisition and at the start of the 
study, and through daily observation of behaviour and appetite. Specialized 
veterinary personnel (SR) made these observations. Turtles were divided 
according to the inclusion group (I or II) into two different 300 L plastic 
pools, with a water depth of 20 cm, water temperature of 27°C, and custom-
built mechanical and biological filtration. A dry basking area was heated to 
30°C using an infrared lamp. Ambient temperature in the room varied from 
25 to 26°C (electronic temperature sensors assured the constant temperature 
in both the water and basking area). Turtles were fed with a floating pelleted 
diet (a mix of fish and soy bean flour supplemented with vitamins and 
calcium chloride) three times per week. Animal care and handling was 
performed according to the provision of the EC council Directive 86/609 
EEC and also according to Institutional Animal Care and Use directives 
issued by the Animal Welfare Committee of the Pisa University, which 
approved the study protocol (Protocol number 37070/2013). 
 
3. Experimental design 
Turtles were randomly assigned to two treatment groups, using slips of 
paper marked with the numbers 1-9, selected blinded from a box. A single-
dose, single-treatment, unpaired, two-period crossover design was used. 
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Each turtle in group I (n = 5) received a single IM dose of TAP (5 mg/mL) at 
5 mg/kg in the proximal front limb. This dose was selected based on 
previous information describing the effectiveness of TAP in rabbits (Giorgi 
et al., 2013). Group B (n = 4) received a single IM injection of saline (0.9% 
NaCl) (equivalent volume to opioid volumes) of TAP. A 1-month washout 
period was observed, to ensure complete metabolism and excretion of TAP. 
After this period, the groups were rotated and the experiment was repeated 
(second period). A fresh drug solution was prepared at this point. By the end 
of the study, each turtle had received both the saline and TAP treatment. 
Blood samples (1 mL) were collected from the subcarapacial venipuncture 
site at 0, 1, 2, 4, 6, 10, and 24, h after TAP administration and placed in 
collection tubes containing lithium heparin (MiniCollect, Greiner Bio-One). 
Specimens were centrifuged at 1,000×g within 30 min of collection, and the 
harvested plasma was stored at -70°C and used within 15 days of collection. 
 
4. High performance liquid chromatography (HPLC) 
Based on a previously published HPLC technique (Giorgi et al., 2012a), 
the analytical method was re-validated for turtle plasma samples. The HPLC 
system was an LC Waters (Waters, USA) consisting of quaternary gradient 
system (600 Controller, Waters, USA), in-line degasser (model AF, Waters, 
USA), photodiode array detector (2998 model, Waters, USA), multi lambda 
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fluorescence detector (model 2475, Waters, USA) and autosampler (model 
717 plus, Waters, USA). Data was processed using Empower ProTM 
software (Waters, USA). The chromatographic separation assay was 
performed with a SunFire C18 analytical column (150 x 4.6 mm inner 
diameter, 5 µm particle size, Water), maintained at 25°C. The mobile phase 
consisted of ACN (A): 0.2% acetic acid (B) at a flow rate of 1 mL/min. 
Excitation and emission wavelengths were set at 273 and 298 nm, 
respectively. The linear gradient elution system was performed as follows: 5-
95% B (0-20 min), 95-5% B (20-25 min) and 5% B isocratically (25-32 min). 
 
5. Preparation of plasma samples 
Briefly, 50 µL of IS solution (0.5 µg/mL) and 0.2 mL 2 mM borate 
buffer, adjusted to pH 9.3, were added to a 1.5 mL polypropylene snap cap 
tube (Sarsedt, USA) containing 0.5 mL of plasma. After vortex-mixing, 0.4 
mL of extraction solvent (Et2O:CH2Cl2 7:3 v/v) was added, the tube was then 
placed in a vortex for 30 s, shaken for 5 min, and then centrifuged for 10 min 
at 15,625×g. The organic layer (0.3 mL) was then transferred into a clean 1.5 
mL polypropylene snap cap conical tube, placed in a vortex and then shaken 
with 0.2 mL of back-extraction solvent (0.05 M HCl:ACN 1:1 v/v) for 5 min, 
before being centrifuged for 10 min at 15,625×g. The aqueous phase (50 µL) 
was injected onto the HPLC system. 
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6. Pharmacokinetic evaluation 
The pharmacokinetic calculations were carried out using WinNonlin v 
5.3 (Pharsight, USA). Maximum concentration (Cmax) of TAP in plasma and 
the time required to reach Cmax (Tmax) were predicted from the data. The 
terminal rate constant (λ) was determined from the slope of the terminal 
phase of the plasma concentration curve that included a minimum of three 
points. The half-life of the terminal phase (T1/2λz) was calculated using T1/2 = 
0.693⁄λ. The area under the concentration vs. time curve (AUC0-∞) was 
calculated using the linear trapezoidal rule. Changes in plasma concentration 
of TAP were evaluated using the standard non-compartmental analysis, and 
the relative pharmacokinetic parameters were determined using standard 
non-compartmental equations (Gabrielsson and Weiner, 2001). 
 
7. Thermal antinociception experiments 
Just before each blood collection, analgesia experiments were 
conducted by applying infrared thermal stimuli to the plantar surface of the 
turtles’ hind limbs with a plantar antinociception device (Hargreaves’s 
instrument, model 37370, Ugo Basile) according to previously described 
methods (Baker et al., 2011; Sladky et al., 2007; 2008) with slight 
modifications. Turtles were gently dried using a smooth cloth and 
individually placed into clear, plastic boxes (300 × 200 × 150 mm, with a 1 
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mm thickness) on a clear acrylic surface. The room temperature was set at 
25-26° C. An infrared radiation source was activated (70° C) directly below 
the surface upon which the turtle rested the plantar surface of either hind 
limb. Hind limb TWLs were measured by a motion-sensitive timer, which 
stopped automatically when the hind limb was removed from the noxious 
stimulus. The increasing temperature caused the turtle to withdraw the limb, 
and the time to withdrawal was automatically measured. A maximum 
exposure duration of 22.5 s (cut-off time) was allowed to prevent severe 
tissue damage. At each time point, the TWL was measured in one hind limb 
and then the other consecutively. When the difference between the two TWL 
values was > 2 s, a third measurement was obtained (at least 5 min after the 
last of the initial measurements). The observer in the analgesia experiments 
was blinded to treatments received. TWL were measured before drug 
administration (baseline) and at the same time as blood collections.  
The thermal antinociceptive effect was expressed as percentage of 
Maximum Possible Response (% MPR) (Harris and Pierson, 1964), which 
was calculated as: 
%  MPR = 𝑇𝑡𝑒𝑠𝑡 − 𝑇𝑐𝑜𝑛𝑇𝑐𝑢𝑡 − 𝑇𝑐𝑜𝑛 ×100 
where Ttest represents TWL value after injection of TAP, Tcon is TWL 
value after injection of saline (control) and Tcut is the cut-off time (22.5 s). 
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8. Pharmacokinetic/pharmacodynamics (PK/PD) integration 
The relation between the plasma concentration of TAP and % MPR 
was determined by sigmoid Emax model and the PD parameters were 
calculated from the model above. This model is described by the following 
equation (Riviere and Papich, 2013): 
𝐸 = 𝐸! +    (𝐸!"#×𝐶!)(𝐸𝐶!"! + 𝐶!) 
where E is the effect (% MPR) at a specific concentration (C), E0 is the effect 
when the concentration is 0, Emax is the maximum effect (% MPR), EC50 is 
the plasma concentration of TAP that results in 50% of maximum effect, C is 
the concentration of TAP in effect compartment and n is the Hill coefficient. 
The pharmacodynamic calculations were carried out using WinNonlin v 5.3 
(Pharsight, USA). 
 
9. Statistical analysis 
Kolmogorov-Smirnov test was applied to verify data distribution. 
Pharmacodynamic data were evaluated using the two-way ANOVA 
(repeated-measures) to determine statistically significant differences between 
treatment and control values (cross over design). The TAP plasma 
concentrations and the pharmacokinetic and pharmacodynamic parameters 
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are presented as means ± standard error (SE). All analyses were conducted 
using GraphPad InStat (GraphPad Software). In all experiments, differences 
were considered significant if P < 0.05. 
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III. Results 
One hour after the TAP IM administration, some signs of sedation 
were noticed in the animals. Turtles did not appear to be responsive to 
external stimuli (e.g. drying process) and had flaccid limbs and necks 
compared to the control animals. This effect was transient and was almost 
completely resolved at 2 h following drug administration. 
 
1. Pharmacokinetic of tapentadol (TAP) 
Average TAP plasma concentration vs. time curve after IM 
administration of 5 mg/kg in turtles is presented in Fig. 1. The plasma 
concentrations of TAP were in the range (37–1619 ng/mL) and detectable up 
to 24 h, except in three subjects. The corresponding pharmacokinetic 
parameters are shown in Table 1. The theoretical peak plasma drug 
concentration (Cmax) of 1641 ± 749 ng/mL was observed at 1.22 ± 0.44 h 
(Tmax) after injection. TAP was eliminated slowly in turtles with a long 
terminal half-life of 4.04 ± 2.10 h and it showed a large volume of 
distribution (Vz/F) of 4.30 ± 1.79 L/kg. 
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2. Pharmacodynamic of tapentadol (TAP) 
Differences in TWL in control group animals (n = 9) were not 
statistically significant at any point tested. Hence, to establish the TWL 
baseline, all the saline solution data was grouped for each time point. No 
significant difference was found between control data obtained from the two 
study periods either. The T0 was 5.66 ± 0.92 s with average values of the 
whole base line ranging from 5.05 to 7.58 s (Fig 2a). 
Animals given TAP showed an increase in TWL 1 hour after drug 
administration (13.32 ± 6.40 s). Subsequently, TWL decreased in proportion 
to time with significant differences from the saline group still apparent up to 
10 h. The average TWL value in the TAP group after 24 h was 6.27 ± 1.22 s 
which is not significantly different than that of baseline (P = 0.18).  
Mean MPR started at 1.69 ± 1.80 % (T0), increased to a maximum of 
46.68 ± 12.30 % at 1 h and decreased to a minimum of 1.62 ± 2.77 % at 24 h 
(Fig. 2b). The MPR difference between TAP and saline group was still 
significant at 10 h. 
 
3. Pharmacokinetic/pharmacodynamic (PK/PD) integration 
The pharmacokinetic/pharmacodynamic correlations are reported in 
Fig. 3a, b. The mean TAP plasma concentration and % MPR vs. time curves 
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were very similar (Fig. 3a). Average plasma concentration associated with 
maximum % MPR of 46.68 ± 12.30 % was 1619 ± 242 ng/mL. Mean plasma 
concentration at each time point ranged between 37 ng/mL (24 h) and 1619 
ng/mL (1 h), associated with % MPR of 1.62 and 46.68 %, respectively. A 
linear relationship (r2 = 0.99) between TAP plasma concentration and % 
MPR was found (Fig. 3b). 
PK/PD relation was evaluated with of use the values of % MPR 
associated with the plasma concentration of TAP using sigmoid Emax model. 
A value of the maximum antinociceptive effect (Emax) was 96.99 ± 7.13 % 
and the mean value of EC50 was 705 ng/mL. The PD parameters and the 
sigmoidal curve were displayed in Table 2 and Figure 4. 
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Fig.1. Mean plasma concentrations (+ SE) vs. time curve of tapentadol (TAP) 
after IM administration (proximal front limb) in turtles (n = 9). The dotted 
line represents the mean value of EC50 (705 ng/mL). The dashed and dotted 
line shows the MEC (148 ng/mL) reported for humans. 
† Data obtained in six turtles. 
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Fig. 2. (A) Mean (+ SE) TWL vs. time curve in turtles (n = 9) after IM saline 
(open square) and IM tapentadol (TAP) (open circle) administration 
(proximal front limb) (5 mg/kg); (B) mean (+ SE) % MPR after IM 
administration of TAP (5 mg/kg). 
* Significantly different (P<0.05) from saline value (control). 
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Fig. 3. (A) Mean (- SE) experimental plasma concentrations (open circles) of 
TAP and mean (+ SE) % MPR (open squares) vs. time curves in turtles (n = 
9) after IM tapentadol (TAP) administration (proximal front limb) (5 mg/kg); 
(B) mean (± SE) experimental plasma concentrations (open circles) vs. mean 
(± SE) % MPR curve. The dotted line is the computed correlation line 
(experimental plasma concentrations vs. % MPR). Numbers represent time 
order. 
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Fig. 4. Sigmoidal curve of tapentadol (TAP) plasma concentration vs. the 
antinociceptive effect (% MPR). 
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Table 1. Pharmacokinetic parameters after IM injection (proximal front limb) 
of TAP at 5 mg/kg in turtles (n = 9) 
Pharmacokinetic 
parameters  Unit Mean ±SE 
λz  1/h 0.26±0.20 
T1/2λz  h 4.04±2.10 
Tmax h 1.22±0.44 
Cmax  ng/mL 1641±749 
AUCo-∞  h ng/mL 7773±5751 
Vz/F L/kg 4.30±1.79 
CL/F L/min/kg 1.06±0.80 
MRT h 4.74±1.55 
λz, first-order rate constant; T1/2λz, half-life of the terminal portion of the 
curve; Tmax, time at the maximum drug concentration; Cmax, maximum drug 
plasma concentration; AUC0−∞, area under the curve from 0 to infinity; Vz/F, 
apparent volume of distribution; CL/F, apparent total body clearance; MRT, 
mean residence time. 
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Table 2. Sigmoidal Emax model parameters of tapentadol (TAP) after IM 
injection (proximal front limb) of TAP at 5 mg/kg in turtles (n = 9) 
Parameters  Unit Mean ± SE 
Emax %           96.99 ± 7.13 
E0  % 5.92 ± 4.66 
Log EC50 ng/mL 2.85 ± 0.16 
Emax, simulated maximum antinociceptive effecet of TAP, E0, is the 
difference of % MPR value in the control, Log EC50, log plasma 
concentration of TAP associated with half of the maximum antinociceptive 
effect. All data were obtained in six turtles. 
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IV. Discussion 
If it is difficult to define and recognize whether an animal feels pain, it 
is even more challenging to objectively determine whether pain medication 
is effective in exotic animals. In general, to determine the efficacy of drugs 
in any species, it is important to determine the pharmacokinetic and 
pharmacodynamic properties of the drug in that species (Toutain and Lees, 
2004). Knowing the pharmacokinetic values for a particular analgesic is 
often insufficient to determine appropriate doses and dosing frequencies, 
because plasma levels of drugs do not always correlate with analgesia. 
Plasma concentrations can provide guidance for dosing frequencies, but that 
does not always hold true because the duration of effect of analgesics (e.g. 
NSAID) may be much longer than what would be expected from plasma 
levels. The pharmacokinetics of analgesics also vary considerably across all 
species that have been studied, so extrapolating clinical doses and dosing 
intervals from one species to another species is not appropriate (Giorgi, 
2012). 
There is great potential for use of TAP in veterinary species (Giorgi, 
2012). Its PK profiles have been already tested in dogs (Giorgi et al., 2012b), 
cats (Chapter 1) and goats (Chapter 2), and its PK/PD profile assessed in 
rabbits (Giorgi et al., 2013). The previous research has supported that the use 
of TAP in veterinary medicine may be suitable to pain control. However, 
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reptiles seem to react to opioids differently to mammals hence a PK/PD 
study in turtles is essential to understand the effectiveness of this drug. This 
study is the first PK/PD study of TAP in turtles using thermal stimulus pain 
model. 
Several nociceptive tests have been established for use in vertebrates, 
but only a few are available for reptiles. In the present study, the TWL was 
evaluated using a noxious heat radiant model with an automatic motion 
sensor device. This method is easy, fast and non-invasive compared with 
other methods, and turtles can escape the stimuli immediately by moving 
their hind limb. Due to these advantages, many nociceptive tests in red-eared 
slider (Baker et al., 2011; Sladky et al., 2007; 2009) have been carried out by 
this method. The TWL evaluated by Hargreaves’s device has proven to be 
reproducible measure of complex nociceptive behaviour in rodents (Dirig et 
al., 1997) as well as other veterinary species (Kogel et al., 2014; SCHMID et 
al., 2010) and it has been extensively used for pain assessment in reptiles 
(Fleming and Robertson, 2012; Greenacre et al., 2006; Sladky et al., 2009; 
2008; 2007). However, the acute thermal (anti-) nociception may be different 
from acute surgical (anti-) nociception and from longer-lasting pain like 
post-operative pain. For this reason, clinical studies are warranted to assess if 
TAP may or may not be useful in clinical settings at the dose studied here. 
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In an earlier pilot trial conducted on another group of turtles (to set up 
the experimental method), it was noticed that the amount of water residue on 
the turtles’ limbs could affect the TWL measurement. This was in line with a 
previous study characterizing the variables in TWL measurement (Dirig et 
al., 1997). To avoid this issue, the turtles’ hind limbs were completely and 
consistently dried just before blood collection and after each animal had been 
examined, the box surface had to be dried. This procedure was essential to 
reduce the variability of the study. The potential influence of residue water 
on responses to thermal noxious stimuli should be considered in future 
studies. 
In the present study, a different temperature (70° vs. 50° C) was set for 
the beam source compared to previous studies (Baker et al., 2011; Sladky et 
al., 2009; 2007). This variation was needed because the PK/PD design was 
contingent on the blood collection and TWL measurement occurring together. 
If the 50° C setting was used, a result could take several minutes, making the 
PK/PD protocol assumption invalid. 
After IM injection of TAP, plasma drug concentrations were detectable 
up to 24 h. This persistence was longer than that reported in cats (8 h) (Lee et 
al., 2013) and goats (6 h) (Lavy et al., 2014) despite the same dose and route 
being used. TAP in turtles showed slower absorption (Tmax = 1.22 h) than in 
cats (Tmax = 0.25 h) (Lee et al., 2013) and goats (Tmax = 0.17 h) (Lavy et al., 
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2014). Furthermore, TAP in turtles reported a half-life almost twice that 
reported in cats (T1/2λz 4.04 vs 2.28 h) (Lee et al., 2013). TAP is metabolized 
predominantly by glucuronidation in humans (Terlinden et al., 2007), as 83% 
of an oral dose of TAP is converted into and excreted as an inactive 
glucuronated metabolite. Compared to mammals, turtles have a lower liver 
metabolic capacity and slower metabolic rate (Berner and Berner, 1999; 
Penick et al., 1998). These differences may have contributed to the long 
terminal half-life value of TAP found in turtles. 
In a previous study, morphine (1.5 and 6.5 mg/kg SC) produced a 
thermal antinociception effect between 4 and 24 h and 2 and 24 h 
respectively, in red-eared slider (Sladky et al., 2007). Tramadol (10 mg/kg 
SC) produced a long lasting thermal antinociception effect between 6 and 48 
h (Baker et al., 2011). According to Sladky et al (2009), thermal 
antinociception in response to opioids in red-eared slider appeared to be 
attributable mainly to MOR activation with a relatively minor contribution of 
delta-opioid receptor activation. It was assumed that the thermal 
antinociception effect was continued from 2 to 8 h after administration of an 
experimental MOR agonist ((D-Ala2, N-Me-Phe4, Gly5-ol)-enkephalinacetate 
salt) by SC at a dose of 6.6 mg/kg (Sladky et al., 2009). When TAP (5 mg/kg 
IM) was administered to turtles, the analgesic effect occurred within 1 h and 
lasted for 10 h after administration. Compared with other studies, TAP 
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produced a thermal antinociception effect more rapidly than morphine and 
tramadol in turtles. It is likely that onset of analgesic effect with TAP 
depends on the different administration route used (IM vs. SC). There is a 
possibility however, that the change of TWL is not solely the result of an 
antinociceptive effect. The sedation seen following the TAP administration 
might have affected the TWL values, especially at the initial measurements. 
A similar effect has been recently reported in American kestrels (Falco 
sparverius) (Ceulemans et al., 2014). Classical MOR agonists (e.g. morphine) 
cause a long lasting respiratory depression in red-eared slider (Sladky et al., 
2007) because of their strong MOR activation. Unfortunately, respiratory 
rate was not evaluated in this study due to lack of the breathing chamber 
earlier described (Sladky et al., 2007). If MOR and MOR affinity are 
assumed to be similar across the species, it might expected that TAP in 
turtles causes less respiratory depression due to its lower MOR affinity 
compared to morphine and M1, as previously reported in humans 
(Tzschentke et al., 2006). Another variable that might have affected the TWL 
values is the effect of the observer. In the present study the turtles could see 
the investigators taking the observational data. This has been shown to be a 
variable in the response to noxious stimuli in iguanas (Fleming and 
Robertson, 2012). Further studies should be conducted to clarify whether this 
is an issue in turtles. 
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The TAP plasma concentration and effect vs. time curves have shown 
to be in phase (Fig. 3a). Indeed, when antinociception effect is plotted 
against plasma concentration, the plasma concentration and effect form a 
linear correlation (r2 = 0.99) (Fig. 3b.); this varies from an earlier study 
reporting PK/PD of buprenorphine in cats (Robertson et al., 2005). The 
linear relationship between TAP plasma concentration and effect might be 
accounted for by the rapid blood-brain equilibration and its high MOR 
affinity (Tzschentke et al., 2007). This fits with the high lipophilicity of TAP 
(Fejős et al., 2014). 
In this study, simulated value of Emax was 96.99 ± 7.13 % and it is in 
line with the maximum antinocicetive effect of TAP reported earlier in 
various pain models (Tzschentke et al., 2007). The mean value of EC50 in 
this study was 705 ng/mL and the TAP plasma concentration exceeded this 
value for over 4 h (Fig. 1). However, there were large variations in this value 
among turtles and the data-set from some turtles did not allow to apply the 
Emax model. Further PK/PD studies, using different pain model, would be 
needed to clarify these issues. Although the time above EC50 has lasted only 
4 h, the thermal nociceptive behavior was significantly reduced at 10 h after 
TAP administration. It suggested that TAP produces a long lasting effect as 
described in previous study in the rabbit (Giorgi et al., 2013). Moreover, the 
TAP plasma concentration in turtles exceeded the human MEC from 1 to 10 
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h (Fig. 1b) and during this time, thermal antinociceptive effect was noted. 
However, extrapolation of the MEC value from humans to animals should be 
done with caution (Giorgi and Yun, 2012) and verified with larger sample 
size animal studies. 
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Chapter 4. Synergistic Interaction of Tapentadol (TAP) and 
Flupirtine (FLP) in the Rat Orofacial Formalin Test 
 
Abstract 
Combination therapy with two or more analgesics is widely used in 
moderate and severe pain conditions. This combination of multiple 
analgesics with different modes of action can increase the analgesic effects 
and reduce side effects of each drug. The aim of this study is to evaluate the 
antinociceptive effect of tapentadol (TAP) and flupirtine (FLP) in rats, when 
administered separately or in combination, as well as their synergistic 
interaction. 
After IP injection of TAP at different doses (2, 5, 10 and 15 mg/kg), 
the nociceptive behavior was reduced with dose-dependent manner in both 
phase I and II. Conversely, IP injection of FLP at different doses (0.6, 1.6, 
3.3, 6.6 and 16.6 mg/kg) induced dose-dependent antinociceptive effect in 
phase II only. TAP was more potent and effective than FLP. The interaction 
between TAP and FLP were synergistic in phase II with an interaction index 
(γ) of 0.50 ± 0.24. The data reported in this study indicates that FLP 
enhances the antinociceptive effect of TAP and this drug combination is 
useful in the treatment of chronic pain.
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I. Introduction 
Opioids are widely used in treatment of moderate and severe pain in 
veterinary medicine. Indeed, they are the most effective class of drugs for 
controlling pain in veterinary medicine (Egger et al., 2013). However, 
persistent use of opioids in the relief of moderate and severe pain induces 
problem and unwanted side effects such as nausea, emesis, constipation and 
respiratory depression can be induced by long lasting treatment (Egger et al., 
2013). 
It is difficult to achieve effective pain control using a single analgesic 
due to development of tolerance and unwanted side effects. Combination 
therapy of different analgesic drugs offers an effective analgesia at reduced 
doses of individual agents, which may decrease the severity of the dose-
related side effects (Playford et al., 1991; Raffa, 2001). Furthermore, 
combining agents with different modes of action may provide multimodal 
coverage of a broad spectrum of pain (Raffa, 2001). Several studies of 
combination of opioids with other classes have been demonstrated in various 
animal models (Abass et al., 2014; Argüelles et al., 2002; Díaz-Reval et al., 
2010; Isiordia-Espinoza et al., 2011; Moreno-Rocha et al., 2012; Zhang et al., 
2011). 
Tapentadol (TAP) is an atypical opioid with dual mechanisms of action. 
Recently, it has been launched in the market for treatment of pain in humans. 
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TAP has received attention in the veterinary medicine due to its efficacy in 
pain control (Biondi et al., 2013; Etropolski et al., 2011; Schwartz et al., 
2011; Vadivelu et al., 2011) and good safety profile (Imanaka et al., 2013; 
Lange et al., 2010; Schwartz et al., 2011) compared with classic opioids in 
human being. Recently, it has been tested in veterinary medicine, and a good 
profile of efficacy has been reported (Giorgi et al., 2013). 
Flupirtine (FLP) is a centrally acting non-opioid analgesic that 
produces muscle relaxation (kumar et al., 2014). It is the first representative 
of the class of selective neuronal potassium channel openers (SNEPCO) 
(Aghajanian and VanderMaelen, 1982) and FLP facilitates the generation of 
the neuronal hyperpolarizing current (M-current). Thus, FLP decreases 
neuronal excitability by increasing the M-current (Kornhuber et al., 1999). 
FLP also inhibits the N-methyl-D-aspartate (NMDA) receptor indirectly 
(Singal et al., 2012). Furthermore, the muscle relaxant action of FLP can 
assist in the treatment of pain associated with spasticity and chronic 
musculoskeletal pain (Mueller-Schwefe, 2003; Wörz et al., 1995).  
Molecules that inhibit the NMDA receptor are likely to have 
synergistic or additive effects with other analgesics, particularly opioids 
(Kolosov et al., 2012). Indeed, it has been demonstrated that the combination 
of FLP and opioids appear to have synergistic interactions (Capuano et al., 
2011; Kolosov et al., 2012). However, there is no drug interaction study 
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between TAP and FLP. This study investigated whether combining FLP with 
TAP can enhance the antinociceptive effect in the orofacial formalin test 
more than either drug alone. 
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II. Materials and Methods 
1. Drugs 
TAP hydrochloride was supplied as a pure powder (> 99.8% purity) 
from Bepharm (Shanghai, China). Flupirtine was purchased as a commercial 
injection formula from Sigma Aldrich (St Louis, MI, USA). All drugs were 
diluted in sterile saline solution. The drug solutions were freshly prepared 
before experiments. 
 
2. Animals 
Male Wistar rats aged 7-8 weeks and weighing (200-220 g) were used. 
Animals were obtained from the Orient Bio Inc. (Gyeonggi-do, South Korea) 
and housed at 22°C on a 12 h dark-light cycle, with free access to food and 
water. Rats were judged to be in good health based on physical examination 
at the time of acquisition and at the start of the study, and through daily 
observation of behaviour and appetite. Before experiments, the animals were 
placed in the testing box for observation of behavior for at least 1 h in order 
to adapt to the environment. The animals were used only once and sacrificed 
using CO2 after the experiment. All experiments were performed according 
to guidelines established by the Chungnam National University Institutional 
Animal Care and Use committee. This study was approved by the Local 
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Ethical Committee of Chungnam National University (Protocol No. CNU-
00437). 
 
3. Experimental design 
Independent groups were used to describe the time course of the 
response for each drug. Groups for each drug (n = 6, each group) were 
received IP administration of saline or increasing doses of either TAP (2, 5, 
10 and 15 mg/kg) or FLP (0.6, 1.6, 3.3, 6.6, and 16.6 mg/kg) of the same 
volume. Sterile saline was administered to control groups. Each experimental 
session included a control group to reduce variability of the result. After 
antinociception assessment of each drug, experimental ED30 values of each 
drug were determined. The values of ED30 add were calculated from the 
following equation (Tallarida, 2002): 
𝐸𝐷!"  𝑎𝑑𝑑 = 𝐸𝐷!"  𝑓𝑙𝑢𝑝𝑖𝑟𝑖𝑡𝑖𝑛𝑒𝑝! + 𝑅𝑝!  
where ED30 flupirtine is the experimental ED30 of FLP, p1 and p2 are the 
proportions of each FLP and TAP in the total mixture, respectively, and R is 
the relative potency that is the ratio of ED30 of FLP alone to ED30 of TAP 
alone. Subsequently, a combination of TAP and FLP in a fixed ratio (1:1) 
was administrated IP at dose of ED30 add/2, ED30 add /4 and ED30 add. All 
drugs or saline were given 30 min before administration of 2.5% formalin. 
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4. Orofacial formalin test and antinociception assessment 
The orofacial formalin test used in this study was previously described 
(Raboisson and Dallel, 2004). Briefly, 50 µl of 2.5% formalin solution 
diluted in isotonic saline was injected into the right upper lip subcutaneously, 
with a 31-gauge needle. After the injection, rats were placed in a glass 
chamber (30 x 30 x 30 cm) with mirrored sides for observation of behaviors. 
A video-camera was placed 1 m from the chamber and the behaviors of the 
rats were recorded for 45 min and the videos were analyzed using the 
JWatcher program developed by Dan Blumstein's Lab (University of 
California, Los Angeles) and the Animal Behaviour Lab (Macquarie 
University, Sydney). The recording video was divided into 15 blocks of 3 
min and the number of seconds that the animals spend rubbing the injected 
site with the ipsilateral fore- or hindpaw was measured for each 3 min block. 
Time courses of the response to formalin for all drugs were determined as 
mean time of face rubbing up to 45 min. The nociceptive response induced 
by formalin is biphasic with the following phases; phase I was early and 
short-lasting (3-5 min) followed by a quiescent period (10-15 min); phase II 
was a prolonged (20-40 min) tonic phase (Raboisson and Dallel, 2004). In 
this study, the first 3 blocks (0-9 min) and 5 blocks (15-30 min) were 
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considered the first and second phase, respectively. The quiescent period (2 
blocks, 9-15 min) was not included in the calculations. 
The degree of nociception was assessed as the area under curve (AUC) 
of the time course of response (face rubbing). The AUC of both phases for 
each drug and combination were calculated by trapezoidal rule. 
Antinociceptive effect of both phases were established based on the 
percentage maximum possible effect (%MPE) calculated according to the 
following equation (Argüelles et al., 2002): 
%  MPE   =    (AUC  vehicle  −   AUC  drug)AUC  vehicle   ×  100 
where AUC vehicle represents the mean AUC of saline treatment groups and 
AUC drug represent the mean AUC of each drug treatment groups. 
 
5. Isobolographic analysis 
An isobolographic analysis was performed to evaluate the interaction 
between TAP and FLP according to the method previously described by 
(Tallarida, 2002). TAP and FLP showed different antinociceptive effects. As 
expected, TAP showed an antinociceptive effect both in phase I and II, while 
FLP was effective in phase II only. Thus, only the antinociceptive effect in 
phase II was used to calculate isobolographic analysis parameters. 
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First, the dose-response curves for phase II were examined and log 
dose-response curves were fitted using a non-linear regression analysis for 
the phase II of the orofacial formalin test. In this study, the maximum effect 
of FLP did not reach 50% of the total effect. The experimental ED30 values 
were used to determine ED30 add value for the combination study. Moreover, 
TAP and FLP showed a different maximum of the antinociceptive effect. 
The doses for FLP (less potent) were taken as equivalent dose of ED30 
fractions of TAP (more potent) for IP administration. After administration of 
drug mixture at different doses (ED30 add, ED30 add/2 and ED30 add/4), the 
experimental ED30 (ED30 comb) was calculated from the dose–response 
curves of the combined drugs using standard linear regression analysis of log 
dose–response. The isobologram was constructed by connecting the ED30 of 
the FLP plotted on the abscissa with the ED30 of TAP plotted on the ordinate 
to obtain the additive line. The variance of ED30 add was evaluated 
according to the previous study (Tallarida, 2002). 
The interaction index (γ) is a measure of the degree of synergism or 
sub-additivity. The interaction index (γ) was calculated as follows:  
γ = ED30 comb / ED30 add 
when the interaction index (γ) is close to 1, the interaction is additive. Values 
higher or lower than 1 indicates sub-additivity or synergism, respectively. 
 
119 
6. Statistical analysis 
Dose-response data were evaluated using the one-way ANOVA 
(repeated-measures) to determine statistically significant differences between 
treatments and control values. Statistical significance between theoretical 
ED30 (ED30 add) and experimental ED30 (ED30 comb) was evaluated using 
Student’s t-test. All analyses were conducted using GraphPad InStat 
(GraphPad Software) and Pharm tools pro trials (The McCary Group Inc.). 
All data were represented as mean ± standard error (SE). In all experiments, 
P values lower than 0.05 (P < 0.05) were considered significant. 
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III. Results 
1. Antinociceptive effect of Flupirtine (FLP) 
After injection of 2.5% diluted formalin solution, a typical pattern of 
face rubbing behavior was produced with two distinct phase; phase I, a 
phasic period lasting 10min after injection and a phase II, a tonic period due 
to sensitization mechanisms (Fig. 1). Time courses of response after IP 
administration of FLP in the range 0.6-16.6 mg/kg were presented in Fig. 1 
and show a dose-dependent reduction in face rubbing behavior. Fig. 2 
displays anitinociceptive effects (% MPE) of FLP in the range 0.6-16.6 
mg/kg both in the first and second phase. In phase I, all tested doses of FLP 
failed to reduce nociceptive behavior (Fig. 1 and 2A). In phase II, FLP 
showed a dose-dependent reduction of nociceptive behavior and significantly 
increased % MPE in treatment groups at 3.3, 6.6 and 16.6 mg/kg compared 
to control (Fig. 2B). The mean MPE value in phase II increased to a 
maximum of 30.06 ± 8.31% in the 16.6 mg/kg FLP injection group. 
 
2. Antinociceptive effect of tapentadol (TAP) 
All doses of TAP that were tested reduced nociceptive behavior both in 
the first and second phases (Fig. 1B) in a dose-dependent manner. 
Particularly, in phase II, TAP (15 mg/kg) produced a greater antinociceptive 
121 
effect (% MPE) of 72.34 ± 2.81% than FLP (16.6 mg/kg, 30.06 ± 5.31%) 
(Fig. 3B). TAP significantly increased % MPE in groups with 5, 10 and 15 
mg/kg injection compared to control (Fig. 3B) in both the first and second 
phases. 
 
3. Isobolographic analysis for combination 
After an administration of drugs mixture, nociceptive effects were 
reduced in a dose-dependent manner (data not shown). 
Mean (± SE) values of the theoretical and experimental ED30 for 
combination were 8.34 ± 0.47 and 4.20 ± 1.21 mg/kg, respectively (Table 1). 
The ED30 comb value was significantly lower than the ED30 add value 
(p<0.05). Isobolographic analysis, using fixed ratio (1:1) ED30 fractions 
showed that combination of TAP and FLP produced antinociceptive effects 
greater than simple additivity (Fig. 4). The ED30 comb value was located in 
the region of the isobologram that indicates synergistic interaction (Fig. 4). 
The interaction index (γ) calculated in this study was 0.50 ± 0.24 that 
indicates synergistic interaction (Table 1). 
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Fig. 1. Effect of flupirtine (A) and tapentadol (B) on the orofacial formalin 
test. Data represented as the mean time of face rubbing ± SE of rats (n = 6 
for each group). 
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Fig. 2. Antinociceptive effect (% MPE) of flupirtine (FLP) with different 
doses in phase I (A) and phase II (B) of the orofacial formalin test. Data 
represented as mean % MPE ± SE of rats (n = 6 for each group). * P < 0.05 
vs. controls. 
124 
 
Fig. 3. Antinociceptive effect (% MPE) of tapentadol (TAP) with different 
doses in phase I (A) and phase II (B) of the orofacial formalin test. Data 
represented as mean % MPE ± SE of rats (n = 6 for each group). * P < 0.05 
vs. controls. 
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Fig. 4. Isobologram for combination of tapentadol (TAP) and flupirtine (FLP) 
in the orofacial formalin test. Data are represented as the means ± SE. 
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Table 1. Parameters of isobolographic analysis for the antinociceptive effect 
of combinations of tapentadol (TAP) and flupirtine (FLP) 
Parameters Drug combination (mg/kg) Mean ± SE 
Theoretical 
(ED30 add) 
8.34 ± 0.47 
Experimental 
(ED30 comb) 
4.20 ± 1.21* 
Interaction 
Index (γ) 0.50 ± 0.24 
* Significantly different (P<0.05) from ED30 add. 
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IV. Discussion 
The orofacial formalin test is a recognized model of acute 
inflammatory nociception related to trigeminal pain. The injection of diluted 
formalin induces tissue injuries and generates behaviors (face rubbing) 
consisting in a biphasic response with a short-lasting first phase followed, 
after a quiescent period, by a second, long-lasting phase caused by 
inflammatory processes. The biphasic pattern of formalin induced 
nociception manifests different underlying mechanisms; the first phase is 
considered to be due to the direct chemical stimulation of nociceptive nerve 
endings (Dallel et al., 1995), while the second phase appears to be related to 
an inflammatory response with central sensitization (Hunskaar and Hole, 
1987). Most of the methods commonly used for the study of nociception 
involve brief noxious stimuli such as noxious thermal (Falcon et al., 1996; 
Hargreaves et al., 1988) or mechanical (Ren, 1999; Rosenfeld et al., 1978) 
stimulation of facial skin, fore- and hind-paw and score thresholds or 
latencies of behavioral escape responses. Compared to these methods, the 
orofacial formalin test can avoid situations that animals turn their head and 
bite or lick the source of discomfort (Raboisson and Dallel, 2004). Indeed, 
the formalin induced models are the closest in nature to clinical pain (Le 
Bars et al., 2001). 
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The coadministration of a second agent with an opioid, which may be 
an analgesic or not, has following benefits: 1) to prolong analgesic duration, 
2) to enhance analgesic efficacy, 3) diminish or minimize adverse effects, 4) 
to reduce opioid tolerance (Smith, 2008). Thus, multiple therapies of opioid 
and analgesics that enhance analgesic efficacy include combination with 
norepinephrine transporter modulators, nonsteroidal anti-inflammatory drugs 
(NSAIDs), local anesthetics, calcium channel blockers, cannabinoids, α2-
adrenergic agonists and GABAB agonists (Smith, 2008). Many of the 
interaction studies with opioid and analgesics have been reported in various 
nociception models (Abass et al., 2014; Capuano et al., 2009; Miranda et al., 
2005; Zhang et al., 2011). In this study, the antinociceptive effect and 
synergistic interaction of the combination with TAP and FLP was evaluated 
by the orofacial formalin test. The results of this study demonstrated that the 
IP administration of TAP resulted in the dose-dependent antinociceptive 
effect in both phases of the orofacial formalin test. However, the IP 
administration of FLP alone reduced the nociceptive activity in the second 
phase only. In the second phase of the orofacial formalin test, TAP was 
superior to FLP both in terms of potency and efficacy. Indeed, the 
administration of the combination of TAP and FLP enhanced the 
antinociceptive effect more than that of TAP or FLP alone. Thus, the 
interaction between TAP and FLP was super-additive (e.g. synergism) with 
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an interaction index of 0.5. These results are similar to the previous 
interaction study of FLP in the orofacial formalin test (Capuano et al., 2011). 
When FLP administered at doses of 3.3, 6.6 and 16.6 mg/kg, it 
produced the significant antinociceptive effect in the phase II. However, the 
administration of FLP at dose of 16.6 mg/kg (% MPR, 30.06%) did not 
produce the maximum antinociceptive effect. This value is lower than that 
reported in earlier study (10 mg/kg, > 45%) despite using of same animals 
and methods (Capuano et al., 2011). This difference might be attributed to 
the different formaline concentration used to induce nociceptive behavior 
(2.5 and 1.5% in this and Capuano et al., study, respectively). According to 
the Raboisson et al. (2004), it was reported that concentration-dependent 
nociceptive behavior is induced by formalin in a range of 0.5-2.5%. 
Therefore, the differences of nociception intensity might be related to the 
different concentrations of formalin. The concentration of formalin 2.5% was 
determined from an earlier pilot test because the concentration of 1.5% 
formalin was insufficient to induce the nociceptive behavior. 
FLP is a non-opioid analgesic acting at the level of KCNQ channels for 
the treatment of a variety of pain states (Devulder, 2010). Drugs that 
modulate KCNQ channels may be useful in the treatment of pain. FLP has 
been investigated for its potential for use in veterinary medicine (Giorgi and 
Owen, 2013) and that FLP was found to be more effective than pentazocine 
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in post-surgery pain, but was comparable to pentazocine in cancer-related 
pain (Klawe and Maschke, 2009). FLP produced significant antinociceptive 
effects in the tail-flick test (Szelenyi et al., 1989) and was superior to 
tramadol for cancer-associated pain (Kolosov et al., 2012). However, its use 
has been limited to musculoskeletal pain due to side effects including 
dizziness, somnolence and cognitive impairment (Herrmann et al., 1993). 
FLP has become of interest again due to its indirect NMDA antagonism, 
even though there is no interaction with the binding sites of the NMDA 
receptor (Jakob and Krieglstein, 1997). 
FLP significantly enhanced the antinociceptive effect of morphine in 
combination in the carrageenan paw inflammation and streptozocin-induced 
diabetic neuropathy pain models (Goodchild et al., 2008a). Moreover, 
synergistic interaction of the combination of FLP and tramadol, an atypical 
opioid, was observed in the orofacial formalin test (Capuano et al., 2011). 
Previous studies showed that the combination of opioids and FLP 
produced a synergistic interaction (Capuano et al., 2011; Goodchild et al., 
2008a; 2008b; Kolosov et al., 2012). Indeed, results reported in this study 
confirmed that FLP significantly increases the antinociceptive effect of TAP. 
FLP showed indirect NMDA receptor antagonism via activation of voltage 
independent potassium channels (Kornhuber et al., 1999). The generation of 
M-current is facilitated through the opening of potassium channels and the 
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opening of these channels which controls neuronal excitability (Orhan et al., 
2012). Thus, the NMDA antagonism of FLP reduces hyperexcitation of the 
nociceptive neurons and it allows reduction in the therapeutic dose of opioids. 
Therefore, the co-administration of FLP with opioids can improve the 
efficacy of opioids and thus lower side effects by reduction of the doses 
required for the analgesic effect. 
In this study, TAP produced an antinociceptive effect like that 
observed in previous combination studies (Schiene et al., 2011). Both of 
TAP and FLP showed an antinociceptive effect each and the combination of 
TAP and FLP displayed the synergistic interaction. In conclusion, the co-
administration of FLP with TAP is regarded as useful in treatment of pain, 
because of its potential lower side effects if compared to classic opioids.  
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General Conclusion 
Tapentadol (TAP) is a novel opioid analgesic drug available for human 
medicine with peculiar mechanism of action and safety profile. It is also a 
promising molecule for pain relief for animals, even though having not yet 
been introduced in veterinary medicine. With this background in mind, basic 
and applied pharmacological investigations have been carried out in order to 
employ it as a pain killer in animals. 
In these investigations, pharmacokinetic characterizations of TAP were 
evaluated in a wide range of animal species: the cat as a companion animal, 
the goats as a food producing animal, and the turtle as an exotic animal. Its 
pharmacodynamic profiles were also studied using the same animal species. 
Its PK/PD relationship was elucidated for its practical application in clinical 
setting. Drug interaction between TAP and FLP has been evaluated for their 
analgesic synergistic effect. 
When TAP was administered intravenously, intramuscularly and 
subcutaneously in cats, its side effects were more severe and longer via IV 
administration if compared to IM and SC administrations. Adverse effects 
such as ataxia were noticed in goats given IV, as opposed to IM. On the 
other hand, pharmacokinetic parameters from IM administration appeared to 
be suitable to give reliable plasma concentrations of TAP. In addition, IM 
bioavailabilities in cats and goats were relatively high, in agreement with 
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high IM bioavailabilities reported for other opioids. From the viewpoint of 
its administration, IM dosing is regarded to be suitable in cats and goats. 
After IM administration of TAP, there were large interspecies variations in 
its half-lives and Tmax between mammals (cats, goats) and reptiles (turtles). 
The average half-life value in turtles was approximately two times higher 
than those in cats and goats. TAP showed slower absorption and elimination 
in turtles as compared to cats and goats. Between the earlier mentioned two 
mammals, the half-life in cats was slightly longer than that in goats, however, 
other pharmacokinetic parameters were similar in these two animal species. 
It is hence postulated that its use needs some caution in turtles, particularly 
with liver and kidney dysfunction. 
TAP produced excellent thermal antinociception in turtles. The thermal 
antinociceptive effect occurred rapidly and lasted as long as 10 hours. From 
the PK/PD study, a significant antinociceptive effect started to generate in 
above the plasma concentrations > 154 ng/mL assessed by the thermal 
stimuli test.  
In this study, we had a scientific result that TAP exerted favorable 
analgesic effects in turtles for the first time, though still necessitating the 
elucidation of its safety profile before its active usage. Nevertheless, the 
results obtained in this work could pave the way for further research on its 
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potential use for reptiles in general. Needless to say, it can be an attractive 
option for antinociception in mammals as well.  
Either TAP or FLP did produce antinociceptive effects in the orofacial 
formalin test after IP injection in rats. On the other hand, the combination of 
TAP and FLP resulted in a synergistic antinociceptive effect. Therefore, this 
co-administration is considered to enhance the antinociceptive effect of both 
drugs. The combination of TAP and FLP is hence proposed as a new 
combination to be tested in veterinary clinical trials. 
